<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00935</drugbank-id>
  <drugbank-id>APRD01158</drugbank-id>
  <name>Oxymetazoline</name>
  <description>A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)</description>
  <cas-number>1491-59-4</cas-number>
  <unii>8VLN5B44ZY</unii>
  <average-mass>260.3746</average-mass>
  <monoisotopic-mass>260.1888634</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For treatment of nasal congestion and redness associated with minor irritations of the eye</indication>
  <pharmacodynamics>Oxymetazoline a adrenergic alpha-agonists, direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis.</pharmacodynamics>
  <mechanism-of-action>Oxymetazoline is a direct acting sympathomimetic amine, which acts on alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa. It produces vasoconstriction, resulting in decreased conjunctival congestion in ophthalmic. In nasal it produces constriction, resulting in decreased blood flow and decreased nasal congestion.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as xylenols. These are aromatic compounds that contain a xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups, and at least one hydroxyl group.</description>
    <direct-parent>Xylenols</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Xylenes</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carboxamidines</alternative-parent>
    <alternative-parent>Carboximidamides</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidazolines</alternative-parent>
    <alternative-parent>Imidolactams</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Ortho cresols</alternative-parent>
    <alternative-parent>Para cresols</alternative-parent>
    <alternative-parent>Phenylpropanes</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>m-Xylenes</alternative-parent>
    <substituent>2-imidazoline</substituent>
    <substituent>Amidine</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Carboximidamide</substituent>
    <substituent>Carboxylic acid amidine</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidolactam</substituent>
    <substituent>M-xylene</substituent>
    <substituent>O-cresol</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>P-cresol</substituent>
    <substituent>Phenol</substituent>
    <substituent>Phenylpropane</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Xylenol</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000821</drugbank-id>
      <name>Oxymetazoline hydrochloride</name>
      <unii>K89MJ0S5VY</unii>
      <cas-number>2315-02-8</cas-number>
      <inchikey>BEEDODBODQVSIM-UHFFFAOYSA-N</inchikey>
      <average-mass>296.836</average-mass>
      <monoisotopic-mass>296.165541139</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline</synonym>
    <synonym language="english" coder="">3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol</synonym>
    <synonym language="english" coder="">6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol</synonym>
    <synonym language="english" coder="">6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol</synonym>
    <synonym language="english" coder="">Oximetazolinum</synonym>
    <synonym language="spanish" coder="inn">Oxymetazolina</synonym>
    <synonym language="english" coder="inn">Oxymetazoline</synonym>
    <synonym language="french" coder="inn">Oxym√©tazoline</synonym>
    <synonym language="latin" coder="inn">Oxymetazolinum</synonym>
    <synonym language="english" coder="">Oxymethazoline</synonym>
    <synonym language="english" coder="">Oxymetozoline</synonym>
  </synonyms>
  <products>
    <product>
      <name>12 Hour Nasal</name>
      <labeller>Altaire Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59390-036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>12 Hour Nasal</name>
      <labeller>Meijer Distribution</labeller>
      <ndc-id/>
      <ndc-product-code>41250-301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>12 Hour Nasal</name>
      <labeller>Healthlife of Usa</labeller>
      <ndc-id/>
      <ndc-product-code>69517-613</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>12 Hour Nasal</name>
      <labeller>Select Brand Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>15127-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-03-01</started-marketing-on>
      <ended-marketing-on>2020-04-30</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>12 Hour Original Nasal Decongestant</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>50 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>12 Hour Original Nasal Decongestant</name>
      <labeller>Sheffield Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>11527-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>50 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>7 Select Nasal</name>
      <labeller>7-Eleven</labeller>
      <ndc-id/>
      <ndc-product-code>10202-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-05</started-marketing-on>
      <ended-marketing-on>2019-10-23</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>7 Select Original Nasal</name>
      <labeller>7-ELEVEN, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>10202-849</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aesb - Oxymetazoline Hydrochloride Nasal Solution USP, 0.025%</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02483106</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Afrin</name>
      <labeller>Navajo Manufacturing Company Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67751-185</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin Cold</name>
      <labeller>Schering Plough</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245573</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-28</started-marketing-on>
      <ended-marketing-on>2006-08-01</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Afrin No Drip Extra Moisturizing</name>
      <labeller>Famar Montreal Inc</labeller>
      <ndc-id/>
      <ndc-product-code>69213-1783</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin No Drip Extra Moisturizing</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-1783</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin No Drip Original Pump Mist</name>
      <labeller>Famar Montreal Inc</labeller>
      <ndc-id/>
      <ndc-product-code>69213-3142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin No Drip Original Pump Mist</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-3142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin No Drip Severe Congestion</name>
      <labeller>Famar Montreal Inc</labeller>
      <ndc-id/>
      <ndc-product-code>69213-1350</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin No Drip Severe Congestion</name>
      <labeller>Bayer HealthCare LLC</labeller>
      <ndc-id/>
      <ndc-product-code>11523-1350</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin No Drip Sinus Pump Mist</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-1702</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-31</started-marketing-on>
      <ended-marketing-on>2018-06-01</ended-marketing-on>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin No-Drip Allergy Sinus</name>
      <labeller>Bayer HealthCare LLC</labeller>
      <ndc-id/>
      <ndc-product-code>11523-3220</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin Original</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-1167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-07-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin Original</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-7016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin Original Pump Mist</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-1159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-07-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin Severe Congestion</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-7020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrin Sinus</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-4112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-30</started-marketing-on>
      <ended-marketing-on>2018-04-01</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anefrin Nasal</name>
      <labeller>Walgreen</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-28</started-marketing-on>
      <ended-marketing-on>2014-08-22</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anefrin Nasal Extra Moisturizing</name>
      <labeller>Walgreen</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-01</started-marketing-on>
      <ended-marketing-on>2016-03-18</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anefrin Nasal Original</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Assured Nasal Relief</name>
      <labeller>Greenbrier International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>33992-8685</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Assured Nasal Relief</name>
      <labeller>United Exchange Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>65923-387</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Assured Nasal Relief Original</name>
      <labeller>Greenbrier International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>33992-8684</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Assured Severe Congestion Nasal Relief</name>
      <labeller>Greenbrier International, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>33992-5284</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.2 mg/0.4mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>AVON HeXashield Congestion Relief Original</name>
      <labeller>TAI GUK PHARM. CO., LTD.</labeller>
      <ndc-id/>
      <ndc-product-code>43136-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Basic Care Nasal</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-7388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Basic Care No Drip Nasal</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-7494</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Being Well Nasal 12 Hour</name>
      <labeller>Save-A-Lot Food Stores Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>46994-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Best Choice</name>
      <labeller>Best Choice (Valu Merchandisers Company)</labeller>
      <ndc-id/>
      <ndc-product-code>63941-716</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Best Choice</name>
      <labeller>Best Choice (Valu Merchandisers Company)</labeller>
      <ndc-id/>
      <ndc-product-code>63941-720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Best Choice Allergy Sinus</name>
      <labeller>Best Choice (Valu Merchandisers Company)</labeller>
      <ndc-id/>
      <ndc-product-code>63941-721</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Best Choice Maximum Strength</name>
      <labeller>Best Choice (Valu Merchandisers Company)</labeller>
      <ndc-id/>
      <ndc-product-code>63941-715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Best Choice Maximum Strength</name>
      <labeller>Best Choice (Valu Merchandisers Company)</labeller>
      <ndc-id/>
      <ndc-product-code>63941-718</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Best Choice Ultra Fine Mist</name>
      <labeller>Best Choice (Valu Merchandisers Company)</labeller>
      <ndc-id/>
      <ndc-product-code>63941-726</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Breaze Nasal Moisturizing</name>
      <labeller>Samson Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>20146-4000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Breaze Nasal Sinus Colds and Allergies</name>
      <labeller>Samson Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>20146-4006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Care One Nasal</name>
      <labeller>American Sales Company</labeller>
      <ndc-id/>
      <ndc-product-code>41520-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Care One Nasal Extra Moisturizing</name>
      <labeller>American Sales Company</labeller>
      <ndc-id/>
      <ndc-product-code>41520-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Care One Nasal Original</name>
      <labeller>American Sales Company</labeller>
      <ndc-id/>
      <ndc-product-code>41520-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Care One Nasal Sinus</name>
      <labeller>American Sales Company</labeller>
      <ndc-id/>
      <ndc-product-code>41520-817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CareOne Severe Congestion Nasal</name>
      <labeller>American Sales Company</labeller>
      <ndc-id/>
      <ndc-product-code>41520-108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Circle K Congestion Relief</name>
      <labeller>Lil' Drug Store Products, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>66715-5760</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Claritin Allergy Decongestant</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243690</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-05-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Claritin Eye Allergy Relief</name>
      <labeller>Schering Plough</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243688</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-05-02</started-marketing-on>
      <ended-marketing-on>2012-07-24</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Clear Time</name>
      <labeller>HYVEE INC</labeller>
      <ndc-id/>
      <ndc-product-code>42507-507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-19</started-marketing-on>
      <ended-marketing-on>2019-01-29</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cleartime</name>
      <labeller>Western Family Foods</labeller>
      <ndc-id/>
      <ndc-product-code>55312-126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-13</started-marketing-on>
      <ended-marketing-on>2017-02-03</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clirol Nasal Spray</name>
      <labeller>Complex Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230771</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Congestion Relief Lil Drug Store Products</name>
      <labeller>Lil' Drug Store Products, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>66715-6860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cooling Menthol Nasal Spray</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02428504</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-08</started-marketing-on>
      <ended-marketing-on>2019-08-14</ended-marketing-on>
      <dosage-form>Spray, metered</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cooling Menthol Nasal Spray</name>
      <labeller>Juno Otc Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02460580</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>CVS Health</name>
      <labeller>CVS Pharmacy,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69842-575</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CVS Health Nasal Mist</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-786</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CVS Health No Drip</name>
      <labeller>CVS Pharmacy,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69842-781</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CVS Health No Drip</name>
      <labeller>CVS Pharmacy,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69842-815</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CVS Health Sinus</name>
      <labeller>CVS Pharmacy, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69842-715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CVS Health Sinus Relief</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-787</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.00050 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CVS Health Ultra Fine Mist</name>
      <labeller>CVS Pharmacy, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69842-726</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decongestant Nasal</name>
      <labeller>Salado Sales Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57243-036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-02-01</started-marketing-on>
      <ended-marketing-on>2020-04-30</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decongestant Nasal Mist Long Lasting</name>
      <labeller>Laboratoires Confab Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02213907</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-10-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>DG Health Clear Time</name>
      <labeller>Dolgencorp</labeller>
      <ndc-id/>
      <ndc-product-code>55910-019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DG Health Nasal</name>
      <labeller>DOLGENCORP, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55910-511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dg Health Nasal Original</name>
      <labeller>DOLGENCORP, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55910-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dg Health Sinus Relief</name>
      <labeller>Dolgencorp</labeller>
      <ndc-id/>
      <ndc-product-code>55910-688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-22</started-marketing-on>
      <ended-marketing-on>2017-12-28</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DG health sinus severe</name>
      <labeller>DOLGENCORP, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55910-696</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Discount drug mart Extra Moisturizing</name>
      <labeller>Discount Drug Mart</labeller>
      <ndc-id/>
      <ndc-product-code>53943-720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Discount Drug Mart Maximum Strength Nasal</name>
      <labeller>Discount Drug Mart</labeller>
      <ndc-id/>
      <ndc-product-code>53943-716</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Discount Drug Mart Original Nasal</name>
      <labeller>Discount Drug Mart</labeller>
      <ndc-id/>
      <ndc-product-code>53943-715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Discount Drug Mart Severe Congestion Nasal</name>
      <labeller>Discount Drug Mart</labeller>
      <ndc-id/>
      <ndc-product-code>53943-718</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Discount Drug Mart Severe Nasal</name>
      <labeller>Discount Drug Mart</labeller>
      <ndc-id/>
      <ndc-product-code>53943-726</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dristan 12 Hr</name>
      <labeller>Wyeth Consumer Healthcare Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0573-1191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drixoral Decongestant Nasal Spray</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00740861</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drixoral Nasal Congestion</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02380129</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drixoral No Drip Cooling Menthol</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245580</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drixoral No Drip Extra Moisturizing</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245575</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drixoral No Drip Original Unscented</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245578</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drixoral No Drip With Calming Chamomile</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02362236</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-07</started-marketing-on>
      <ended-marketing-on>2019-02-05</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Equaline Nasal</name>
      <labeller>SUPERVALU INC</labeller>
      <ndc-id/>
      <ndc-product-code>41163-703</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Equaline Nasal</name>
      <labeller>SUPERVALU INC</labeller>
      <ndc-id/>
      <ndc-product-code>41163-343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Equaline Nasal</name>
      <labeller>SUPERVALU INC</labeller>
      <ndc-id/>
      <ndc-product-code>41163-061</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EQUALINE Oxymetazoline HCl Nasal Decongestant No Drip</name>
      <labeller>Supervalu</labeller>
      <ndc-id/>
      <ndc-product-code>41163-716</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Equate Nasal</name>
      <labeller>WAL-MART STORES INC</labeller>
      <ndc-id/>
      <ndc-product-code>49035-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Equate Nasal Original</name>
      <labeller>WAL-MART STORES INC</labeller>
      <ndc-id/>
      <ndc-product-code>49035-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exchange Select Nasal</name>
      <labeller>Army &amp; Air Force Exchange Service</labeller>
      <ndc-id/>
      <ndc-product-code>55301-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exchange Select Nasal</name>
      <labeller>Army &amp; Air Force Exchange Service</labeller>
      <ndc-id/>
      <ndc-product-code>55301-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Moisturizing</name>
      <labeller>Publix Super Markets Inc</labeller>
      <ndc-id/>
      <ndc-product-code>56062-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Moisturizing Nasal Pump Mist Anti Drip</name>
      <labeller>WinCo Foods, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67091-324</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Moisturizing Nasal Spray</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02428660</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Extra Moisturizing Nasal Spray</name>
      <labeller>Juno Otc Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02460572</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Extra Moisturizing No Drip Nasal Walgreens</name>
      <labeller>Walgreens</labeller>
      <ndc-id/>
      <ndc-product-code>0363-7004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Family Care Nasal Relief</name>
      <labeller>United Exchange Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>65923-551</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Family Care Nasal Relief</name>
      <labeller>United Exchange Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>65923-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Family Care Nasal Relief</name>
      <labeller>United Exchange Corp</labeller>
      <ndc-id/>
      <ndc-product-code>65923-570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Family Care Nasal Relief</name>
      <labeller>United Exchange Corp</labeller>
      <ndc-id/>
      <ndc-product-code>65923-571</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>FormuCare Nasal Original</name>
      <labeller>Access Business Group</labeller>
      <ndc-id/>
      <ndc-product-code>10056-329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-10</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Neighbor Pharmacy Nasal</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>24385-498</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-03-16</started-marketing-on>
      <ended-marketing-on>2016-05-06</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Neighbor Pharmacy Nasal</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>46122-165</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Neighbor Pharmacy Nasal</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>24385-352</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Neighbor Pharmacy Nasal</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>46122-347</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Neighbor Pharmacy Nasal Extra Moisturizing</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>24385-067</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Sense Nasal</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-0817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Sense Nasal</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-0065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-03-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Sense Nasal</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-0304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Sense Nasal</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-0388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Health Mart Nasal</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0081</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-11</started-marketing-on>
      <ended-marketing-on>2016-05-06</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Health Mart Nasal</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0080</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Health Mart Nasal</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0079</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Healthy Accents Nasal</name>
      <labeller>DZA Brands LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55316-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Healthy Accents Nasal Original</name>
      <labeller>DZA Brands LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55316-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HEB Nasal decongestant No Drip Extra Moisturizing</name>
      <labeller>H-E-B</labeller>
      <ndc-id/>
      <ndc-product-code>37808-412</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kovanaze</name>
      <labeller>St. Renatus</labeller>
      <ndc-id/>
      <ndc-product-code>69803-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number>NDA208032</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Extra Moisturizing Nasal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>49781-042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mg</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Nasal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>49781-136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-04</started-marketing-on>
      <ended-marketing-on>2018-10-25</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Nasal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>49781-137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-11</started-marketing-on>
      <ended-marketing-on>2014-12-11</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Nasal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>37205-067</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-05</started-marketing-on>
      <ended-marketing-on>2015-07-01</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Nasal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>37205-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-01-22</started-marketing-on>
      <ended-marketing-on>2013-10-24</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Original Nasal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>37205-735</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Original Nasal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>49781-041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mg</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Severe Congestion Nasal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>37205-336</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Long Lasting Decongestant Nasal Spray</name>
      <labeller>Crls</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02454351</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Long Lasting Dristan Mentholated Nasal Spray</name>
      <labeller>Pfizer Consumer Healthcare A Division Of Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01929380</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Long Lasting Dristan Nasal Mist</name>
      <labeller>Pfizer Consumer Healthcare A Division Of Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01929372</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Long Lasting Nasal Mist</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246022</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Long Lasting Nasal Mist</name>
      <labeller>Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239188</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-03-08</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Long Lasting Nasal Mist</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02250861</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Major</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-7006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Marc Glassman Maximum Strength</name>
      <labeller>Marc Glassman, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68998-715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Max Str.Nasal Relief Severe Congestion</name>
      <labeller>Ride Aid</labeller>
      <ndc-id/>
      <ndc-product-code>11822-1232</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Maximum Strength Nasal Decongestant</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>69842-316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>50 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Maximum Strenth Nasal</name>
      <labeller>Walgreens</labeller>
      <ndc-id/>
      <ndc-product-code>0363-7003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MUCINEX Childrens Stuffy Nose</name>
      <labeller>RB Health (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63824-961</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mucinex Full Force</name>
      <labeller>Reckitt Benckiser</labeller>
      <ndc-id/>
      <ndc-product-code>63824-123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mucinex Full Force</name>
      <labeller>RB Health (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63824-125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-01</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mucinex Moisture Smart</name>
      <labeller>RB Health (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63824-124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-01</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mucinex Nasal Moisture Smart</name>
      <labeller>RB Health (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63824-122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-20</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mucinex Sinus-action Congestion &amp; Sinus Nasal Spray</name>
      <labeller>Reckitt Benckiser</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424738</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mucinex Sinus-action Moisture Smart Nasal Spray</name>
      <labeller>Reckitt Benckiser</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424711</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mucinex Sinus-Max Full Force</name>
      <labeller>RB Health (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63824-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-01</started-marketing-on>
      <ended-marketing-on>2020-12-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mucinex Sinus-Max Full Force</name>
      <labeller>RB Health (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63824-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-15</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mucinex Sinus-Max Moisture Smart</name>
      <labeller>Reckitt Benckiser</labeller>
      <ndc-id/>
      <ndc-product-code>63824-126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-01</started-marketing-on>
      <ended-marketing-on>2014-04-30</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MUCINEX SINUS-MAX SEVERE CONGESTION RELIEF SINUS and ALLERGY</name>
      <labeller>RB Health (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63824-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MUCINEX SINUS-MAX SEVERE NASAL CONGESTION RELIEF CLEAR and COOL NASAL</name>
      <labeller>RB Health (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63824-129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nafrine Pediatric Nasal Spray/drops 0.025%</name>
      <labeller>Schering Plough</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02036517</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-31</started-marketing-on>
      <ended-marketing-on>2001-07-18</ended-marketing-on>
      <dosage-form>Solution / drops; Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-2154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-284</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-17</started-marketing-on>
      <ended-marketing-on>2018-04-17</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>We Care Distributor Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70005-038</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-876</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-01</started-marketing-on>
      <ended-marketing-on>2016-01-07</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0335</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>H.E.B.</labeller>
      <ndc-id/>
      <ndc-product-code>37808-021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Kroger</labeller>
      <ndc-id/>
      <ndc-product-code>30142-817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Shopko Stores Operating Co., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>37012-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-19</started-marketing-on>
      <ended-marketing-on>2018-10-29</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Shopko Stores Operating Co., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>37012-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>HYVEE INC</labeller>
      <ndc-id/>
      <ndc-product-code>42507-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-13</started-marketing-on>
      <ended-marketing-on>2019-02-22</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>HYVEE INC</labeller>
      <ndc-id/>
      <ndc-product-code>42507-037</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-12</started-marketing-on>
      <ended-marketing-on>2019-02-19</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-989</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4641</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-6319</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-6623</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-6378</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>DR. FRIEDMAN'S NO MORE NOSEBLEED KIT INC.</labeller>
      <ndc-id/>
      <ndc-product-code>73169-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route/>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-5711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-17</started-marketing-on>
      <ended-marketing-on>2021-01-31</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-701</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Kroger Company</labeller>
      <ndc-id/>
      <ndc-product-code>30142-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Kroger Company</labeller>
      <ndc-id/>
      <ndc-product-code>30142-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Kroger Company</labeller>
      <ndc-id/>
      <ndc-product-code>30142-303</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>H E B</labeller>
      <ndc-id/>
      <ndc-product-code>37808-502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>H E B</labeller>
      <ndc-id/>
      <ndc-product-code>37808-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>Shopko Stores Operating Co., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>37012-901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-2304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal 12 Hour</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal 12 Hour</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Congestion Spray</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02428679</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nasal Congestion Spray</name>
      <labeller>Juno Otc Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02460599</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nasal D</name>
      <labeller>Western Family Foods</labeller>
      <ndc-id/>
      <ndc-product-code>55312-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-17</started-marketing-on>
      <ended-marketing-on>2018-05-21</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal D</name>
      <labeller>Western Family Foods</labeller>
      <ndc-id/>
      <ndc-product-code>55312-817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-26</started-marketing-on>
      <ended-marketing-on>2018-01-17</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal D Original</name>
      <labeller>Western Family Foods</labeller>
      <ndc-id/>
      <ndc-product-code>55312-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-13</started-marketing-on>
      <ended-marketing-on>2018-10-24</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant</name>
      <labeller>Navarro Discount Pharmacies, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>59970-052</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant</name>
      <labeller>Pro Mex Llc</labeller>
      <ndc-id/>
      <ndc-product-code>58988-0193</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant</name>
      <labeller>Kareway Product, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67510-0669</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-07</started-marketing-on>
      <ended-marketing-on>2016-12-31</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal decongestant</name>
      <labeller>H.E.B.</labeller>
      <ndc-id/>
      <ndc-product-code>37808-832</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6761</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant</name>
      <labeller>Kareway Product, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67510-0068</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant</name>
      <labeller>THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.</labeller>
      <ndc-id/>
      <ndc-product-code>72103-333</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-219</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant Extra Moisturizing</name>
      <labeller>Kareway Product, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67510-0069</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant Extra Moisturizing Premier Value</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant Original</name>
      <labeller>Velocity Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>76168-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant Premier Value</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Decongestant Sinus Premier Value</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-307</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-04</started-marketing-on>
      <ended-marketing-on>2018-01-22</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Extra Moisturizing</name>
      <labeller>Hannaford Brothers Company</labeller>
      <ndc-id/>
      <ndc-product-code>41268-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-21</started-marketing-on>
      <ended-marketing-on>2013-08-02</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Extra Moisturizing</name>
      <labeller>Kroger</labeller>
      <ndc-id/>
      <ndc-product-code>30142-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-06-17</started-marketing-on>
      <ended-marketing-on>2017-07-27</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Extra Moisturizing</name>
      <labeller>HYVEE INC</labeller>
      <ndc-id/>
      <ndc-product-code>42507-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-04-02</started-marketing-on>
      <ended-marketing-on>2020-05-06</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Mist</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Mist</name>
      <labeller>Shopko Stores Operating Co., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>37012-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Mist CVS</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-387</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Mist CVS</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-435</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Mist Walgreens</name>
      <labeller>Walgreens</labeller>
      <ndc-id/>
      <ndc-product-code>0363-7000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Original</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-09-15</started-marketing-on>
      <ended-marketing-on>2016-05-06</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Original</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-09-18</started-marketing-on>
      <ended-marketing-on>2016-02-12</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Original</name>
      <labeller>HYVEE INC</labeller>
      <ndc-id/>
      <ndc-product-code>42507-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-11-18</started-marketing-on>
      <ended-marketing-on>2020-07-31</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Relief</name>
      <labeller>Rugby</labeller>
      <ndc-id/>
      <ndc-product-code>0536-1013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-14</started-marketing-on>
      <ended-marketing-on>2018-08-27</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Relief 12-Hour</name>
      <labeller>Rugby</labeller>
      <ndc-id/>
      <ndc-product-code>0536-5005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Relief Rite Aid</name>
      <labeller>Rite Aid</labeller>
      <ndc-id/>
      <ndc-product-code>11822-1230</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasal Sinus</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nasalub Nasal Relief</name>
      <labeller>Genomma Lab</labeller>
      <ndc-id/>
      <ndc-product-code>50066-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>No Drip</name>
      <labeller>Publix Super Markets Inc</labeller>
      <ndc-id/>
      <ndc-product-code>56062-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>No Drip Nasal Mist</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>69842-312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>50 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>No Drip Nasal Mist Nasal Decongestant Severe Congestion</name>
      <labeller>Wal-Mart Stores,Inc.,</labeller>
      <ndc-id/>
      <ndc-product-code>49035-991</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>No Drip Nasal Mist Original</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-796</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>No Drip Original</name>
      <labeller>Velocity Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>76168-600</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>No Drip Premier Value</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>No Drip Severe Congestion Premier Value</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-309</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>No Drip Severe Nasal Mist</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>69842-315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>50 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>No More Nosebleed</name>
      <labeller>DR. FRIEDMAN'S NO MORE NOSEBLEED KIT INC.</labeller>
      <ndc-id/>
      <ndc-product-code>73169-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nostrilla</name>
      <labeller>Insight Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>63736-072</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.0005 mL/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nostrilla</name>
      <labeller>Insight Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>63736-730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ocuclear Oph Dps 0.025%</name>
      <labeller>Schering Plough</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00543454</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on>2003-07-14</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Original</name>
      <labeller>Publix Super Markets Inc</labeller>
      <ndc-id/>
      <ndc-product-code>56062-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ORIGINAL Nasal PUMP MIST No Drip</name>
      <labeller>WinCo Foods, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67091-326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Original No Drip Nasal</name>
      <labeller>Rite Aid</labeller>
      <ndc-id/>
      <ndc-product-code>11822-1231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Original No Drip Nasal Walgreens</name>
      <labeller>Walgreens</labeller>
      <ndc-id/>
      <ndc-product-code>0363-7005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Original Unscented Nasal Spray</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02428687</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Otrivin Medicated No Drip</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464845</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Otrivin Medicated Sinus</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464837</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>OXYMETAZOLINE HCl</name>
      <labeller>Purine Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>58599-027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>OXYMETAZOLINE HCl</name>
      <labeller>Kingston Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71027-013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oxymetazoline HCl</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oxymetazoline HCl</name>
      <labeller>Perrigo New York Inc</labeller>
      <ndc-id/>
      <ndc-product-code>45802-410</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oxymetazoline Hydrochloride</name>
      <labeller>Dynamic Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64762-865</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.2 mg/0.4mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oxymetazoline Hydrochloride</name>
      <labeller>Dynamic Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64762-864</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.2 mg/0.4mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oxymetazoline Hydrochloride</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-875</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oxymetazoline Hydrochloride</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oxymetazoline Hydrochloride</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-418</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oxymetazoline Hydrochloride 12-Hour</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-2030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oxymetazoline Hydrochloride Nasal Spray 0.05%</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02405245</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Oxymetazoline Hydrochloride Nasal Spray 0.05% With Moisturizers</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02405237</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Oxymethazoline HCL</name>
      <labeller>Reliable 1 Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>69618-050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/1</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oxymethazoline HCL</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-5014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/1</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Preferred Plus 12 Hour Nasal Extra Moisturizing</name>
      <labeller>Kinray</labeller>
      <ndc-id/>
      <ndc-product-code>61715-047</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>50.0 mg/100.0mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Preferred Plus 12 Hour Nasal Original</name>
      <labeller>Kinray</labeller>
      <ndc-id/>
      <ndc-product-code>61715-048</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>50 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Preferred Plus Nasal</name>
      <labeller>Kinray</labeller>
      <ndc-id/>
      <ndc-product-code>61715-153</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Preferred Plus Nasal</name>
      <labeller>Kinray</labeller>
      <ndc-id/>
      <ndc-product-code>61715-152</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Publix</name>
      <labeller>Publix Super Markets, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41415-716</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Publix Extra Moisturizing</name>
      <labeller>Publix Super Markets, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41415-720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Publix Maximum Strength</name>
      <labeller>Publix Super Markets, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41415-715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quality Choice</name>
      <labeller>Chain Drug Marketing Association</labeller>
      <ndc-id/>
      <ndc-product-code>63868-699</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quality Choice Maximum Strength</name>
      <labeller>Chain Drug Marketing Association</labeller>
      <ndc-id/>
      <ndc-product-code>63868-698</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quality Choice Nasal</name>
      <labeller>QUALITY CHOICE (Chain Drug Marketing Association)</labeller>
      <ndc-id/>
      <ndc-product-code>63868-079</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quality Choice Nasal Maximum Strength</name>
      <labeller>QUALITY CHOICE (Chain Drug Marketing Association)</labeller>
      <ndc-id/>
      <ndc-product-code>63868-080</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quality Choice Nasal Original</name>
      <labeller>QUALITY CHOICE (Chain Drug Marketing Association)</labeller>
      <ndc-id/>
      <ndc-product-code>63868-077</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rexall Sinus Nasal Pump Mist</name>
      <labeller>Dollar General</labeller>
      <ndc-id/>
      <ndc-product-code>55910-778</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rhofade</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0023-5300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA208552</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rhofade</name>
      <labeller>Aclaris Therapeutics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71180-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>1 g/100g</strength>
      <route>Topical</route>
      <fda-application-number>NDA208552</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rx Act Nasal Extra Moisturizing</name>
      <labeller>H.E.B.</labeller>
      <ndc-id/>
      <ndc-product-code>37808-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-10-12</started-marketing-on>
      <ended-marketing-on>2018-10-24</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rx Act Nasal Original</name>
      <labeller>H.E.B.</labeller>
      <ndc-id/>
      <ndc-product-code>37808-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-02-03</started-marketing-on>
      <ended-marketing-on>2018-10-24</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rx Act Nasal Sinus</name>
      <labeller>H.E.B.</labeller>
      <ndc-id/>
      <ndc-product-code>37808-817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-25</started-marketing-on>
      <ended-marketing-on>2017-11-13</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sbeb - Oxymetazoline Hydrochloride Nasal Solution USP, 0.05%</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02474492</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Severe Congestion Nasal Anti-Drip Nasal Decongestant</name>
      <labeller>WinCo Foods, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67091-325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Severe Congestion Nasal no drip Walgreens</name>
      <labeller>Walgreens</labeller>
      <ndc-id/>
      <ndc-product-code>0363-7001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Shopko Extra Moisturizing Nasal</name>
      <labeller>United Exchange Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>65923-977</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Shopko Original Nasal</name>
      <labeller>United Exchange Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>65923-077</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Shopko Severe Congestion Nasal</name>
      <labeller>United Exchange Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>65923-978</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ShopRite Nasal</name>
      <labeller>Wakefern Food Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>41190-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ShopRite Nasal</name>
      <labeller>Wakefern Food Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>41190-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-26</started-marketing-on>
      <ended-marketing-on>2019-10-15</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Signature Care Nasal Decongestant</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-429</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Signature Care Nasal Decongestant</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-813</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Signature Care Nasal Decongestant</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-589</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Signature Care Nasal Decongestant</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-801</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sinex Complete</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456508</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sinex Moisturizing Ultra Fine Mist</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456516</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sinex Original Ultra Fine Mist</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456494</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sinex Scent Free Ultra Fine Mist</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456486</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sinufrin</name>
      <labeller>Neil Med</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02439484</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>SinuFrin NeilMed</name>
      <labeller>Neil Med</labeller>
      <ndc-id/>
      <ndc-product-code>13709-231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>7.5 mg/15mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sinufrin Plus</name>
      <labeller>Neil Med</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02439492</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>SinuFrin Plus NeilMed</name>
      <labeller>NeilMed Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13709-232</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>7.5 mg/15mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sinus Relief</name>
      <labeller>Hyvee</labeller>
      <ndc-id/>
      <ndc-product-code>42507-688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-07</started-marketing-on>
      <ended-marketing-on>2017-12-28</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sinus Relief</name>
      <labeller>Western Family Foods</labeller>
      <ndc-id/>
      <ndc-product-code>55312-688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-07</started-marketing-on>
      <ended-marketing-on>2017-12-28</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sinus relief</name>
      <labeller>Meijer Distribution</labeller>
      <ndc-id/>
      <ndc-product-code>41250-688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-13</started-marketing-on>
      <ended-marketing-on>2017-12-28</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smart Sense Nasal</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-26</started-marketing-on>
      <ended-marketing-on>2016-07-19</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smart Sense Nasal</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-594</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-01</started-marketing-on>
      <ended-marketing-on>2017-12-28</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smart Sense Nasal Extra Moisturizing</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smart Sense Nasal Original</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smart Sense Pump Mist</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-499</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smart Sense pump mist</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smart Sense sinus relief</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-26</started-marketing-on>
      <ended-marketing-on>2017-12-28</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sound Body 12 Hour Nasal Original</name>
      <labeller>Lee Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>23558-5120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>50.0 mg/100.0mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sound Body Nasal</name>
      <labeller>Big Lots Stores, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50594-719</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sound Body Nasal</name>
      <labeller>Big Lots Stores, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50594-017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sudafed OM</name>
      <labeller>Mc Neil Consumer Healthcare Div. Mc Neil Ppc, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>50580-528</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-01</started-marketing-on>
      <ended-marketing-on>2012-03-31</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark Nasal</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>49348-276</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-13</started-marketing-on>
      <ended-marketing-on>2016-05-06</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark Nasal</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49348-230</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark Nasal</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49348-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark Nasal</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49348-231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark Nasal Original</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49348-028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark no drip</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>49348-472</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-19</started-marketing-on>
      <ended-marketing-on>2016-12-27</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Todays Health Nasal Relief Extra Moisturizing</name>
      <labeller>TAI GUK PHARM. CO., LTD.</labeller>
      <ndc-id/>
      <ndc-product-code>68169-0014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Todays Health Nasal Relief Original</name>
      <labeller>TAI GUK PHARM. CO., LTD.</labeller>
      <ndc-id/>
      <ndc-product-code>68169-0013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Todays Health Sinus Nasal Relief</name>
      <labeller>TAI GUK PHARM. CO., LTD.</labeller>
      <ndc-id/>
      <ndc-product-code>68169-0012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Clear Time</name>
      <labeller>Topco Associates</labeller>
      <ndc-id/>
      <ndc-product-code>36800-559</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Nasal</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Nasal</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Nasal</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Nasal</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-907</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Nasal</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Sinus Nasal</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Sinus Relief</name>
      <labeller>Topco Associates</labeller>
      <ndc-id/>
      <ndc-product-code>36800-688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-29</started-marketing-on>
      <ended-marketing-on>2017-12-28</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Sinus Severe</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-607</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ultra Fine Mist Premier Value</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-04</started-marketing-on>
      <ended-marketing-on>2018-01-26</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Up and up nasal</name>
      <labeller>Target Corporation.</labeller>
      <ndc-id/>
      <ndc-product-code>11673-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Up and Up nasal</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-935</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Up and Up Nasal Extra Moisturizing</name>
      <labeller>Target Corporation.</labeller>
      <ndc-id/>
      <ndc-product-code>11673-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-21</started-marketing-on>
      <ended-marketing-on>2017-02-22</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks QlearQuil 12 Hour Decongestant Moisturizing</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code>37000-410</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-01</started-marketing-on>
      <ended-marketing-on>2019-09-01</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.512 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex 12 Hour</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code>37000-542</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-07-30</started-marketing-on>
      <ended-marketing-on>2009-07-01</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex 12 Hour Decongestant</name>
      <labeller>The Procter &amp; Gamble Manufacturing Company</labeller>
      <ndc-id/>
      <ndc-product-code>37000-434</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-27</started-marketing-on>
      <ended-marketing-on>2021-06-01</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005095 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex 12 Hour Decongestant Nasal</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code>37000-803</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on>2017-10-08</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005055 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex 12 Hour Decongestant Ultra Fine Mist</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code>37000-802</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on>2018-12-10</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005095 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex 12 Hour Decongestant Ultra Fine Mist</name>
      <labeller>The Procter &amp; Gamble Manufacturing Company</labeller>
      <ndc-id/>
      <ndc-product-code>37000-433</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005095 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex 12 Hour Decongestant Ultra Fine Mist Moisturizing</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code>37000-801</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on>2018-10-15</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.000512 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex 12 Hour Nasal Decongestant Ultra Fine Mist Moisturizing</name>
      <labeller>The Procter &amp; Gamble Manufacturing Company</labeller>
      <ndc-id/>
      <ndc-product-code>37000-432</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005095 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex 12 Hour Ultra Fine Mist</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code>37000-543</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-07-30</started-marketing-on>
      <ended-marketing-on>2009-07-01</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex Decongestant Nasal Spray 0.05%</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02008149</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Vicks Sinex Scent Free</name>
      <labeller>The Procter &amp; Gamble Manufacturing Company</labeller>
      <ndc-id/>
      <ndc-product-code>37000-435</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-31</started-marketing-on>
      <ended-marketing-on>2021-12-01</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.05 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex Severe No Drip</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code>37000-527</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex Severe Original</name>
      <labeller>The Procter &amp; Gamble Manufacturing Company</labeller>
      <ndc-id/>
      <ndc-product-code>37000-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005095 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex VapoSpray</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code>37000-683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-25</started-marketing-on>
      <ended-marketing-on>2010-07-06</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005095 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex VapoSpray</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code>37000-682</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-25</started-marketing-on>
      <ended-marketing-on>2010-07-06</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005055 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex VapoSpray</name>
      <labeller>Procter And Gamble</labeller>
      <ndc-id/>
      <ndc-product-code>37000-685</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-25</started-marketing-on>
      <ended-marketing-on>2010-07-06</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.000512 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex VapoSpray</name>
      <labeller>Procter &amp; Gamble Manufacturing GmbH</labeller>
      <ndc-id/>
      <ndc-product-code>64336-683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-29</started-marketing-on>
      <ended-marketing-on>2014-06-27</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005095 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex VapoSpray</name>
      <labeller>Procter &amp; Gamble Manufacturing GmbH</labeller>
      <ndc-id/>
      <ndc-product-code>64336-685</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-25</started-marketing-on>
      <ended-marketing-on>2014-06-27</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.000512 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vicks Sinex VapoSpray</name>
      <labeller>Procter &amp; Gamble Manufacturing GmbH</labeller>
      <ndc-id/>
      <ndc-product-code>64336-682</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-25</started-marketing-on>
      <ended-marketing-on>2014-06-27</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.0005055 g/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Visine L.R.</name>
      <labeller>Johnson &amp; Johnson</labeller>
      <ndc-id/>
      <ndc-product-code>42002-204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-05</started-marketing-on>
      <ended-marketing-on>2016-08-01</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>0.25 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA019407</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Visine L.R. Ophthalmic Sol 0.025%</name>
      <labeller>Pfizer Canada Inc., Consumer Healthcare Division</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01942484</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Visine Workplace</name>
      <labeller>Johnson &amp; Johnson</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02151014</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2016-08-04</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Walgreens 12-Hour Sinus Relief</name>
      <labeller>Walgreen</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-01</started-marketing-on>
      <ended-marketing-on>2014-02-20</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Walgreens Anefrin Severe Congestion Nasal</name>
      <labeller>Walgreen</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0309</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-29</started-marketing-on>
      <ended-marketing-on>2014-02-20</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Walgreens Extra Moisturizing Anefrin Nasal</name>
      <labeller>Walgreen</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-29</started-marketing-on>
      <ended-marketing-on>2014-02-20</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Walgreens Original Anefrin Nasal</name>
      <labeller>Walgreen</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-29</started-marketing-on>
      <ended-marketing-on>2014-02-20</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>WinCo Foods Extra Moisturizing Nasal Relief</name>
      <labeller>Winco Foods</labeller>
      <ndc-id/>
      <ndc-product-code>67091-191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.005 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>WinCo Foods Original Nasal</name>
      <labeller>Winco Foods</labeller>
      <ndc-id/>
      <ndc-product-code>67091-193</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>WinCo Foods Severe Congestion Nasal Relief</name>
      <labeller>Winco Foods</labeller>
      <ndc-id/>
      <ndc-product-code>67091-192</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.05 g/100mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ydyb - Oxymetazoline Hydrochloride Nasal Solution USP, 0.025%</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484102</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zicam</name>
      <labeller>Matrixx Initiatives, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62750-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zicam</name>
      <labeller>Matrixx Initiatives, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62750-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.5 mg/1mL</strength>
      <route>Nasal</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zicam Congestion Relief</name>
      <labeller>Zicam Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02313626</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-27</started-marketing-on>
      <ended-marketing-on>2009-11-20</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zicam Sinus Relief</name>
      <labeller>Zicam Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02313618</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-27</started-marketing-on>
      <ended-marketing-on>2009-11-20</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Dristan 12-Hour</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Duramist Plus</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Genasal Nasal Spray Up to 12 Hour Relief</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Iliadin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Neo-Synephrine 12 Hour Spray</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Nezeril</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Nostrilla 12 Hour Nasal Decongestant</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>OcuClear</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Vicks Sinex 12 Hour Nasal Spray</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Todays Health Nasal Relief Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Todays Health Nasal Relief Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Todays Health Sinus Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymetazoline Hydrochloride</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex 12 Hour Ultra Fine Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex VapoSpray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex 12 Hour</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex VapoSpray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex VapoSpray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nostrilla</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymetazoline Hydrochloride</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymetazoline Hydrochloride</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymetazoline Hydrochloride</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymetazoline Hydrochloride</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Mucinex Full Force</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sudafed OM</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Shopko Severe Congestion Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Shopko Extra Moisturizing Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Shopko Original Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Leader Original Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Leader Severe Congestion Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Assured Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Relief 12-Hour</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Preferred Plus 12 Hour Nasal Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Preferred Plus 12 Hour Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>No Drip Nasal Mist Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sound Body 12 Hour Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex VapoSpray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex VapoSpray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>12 Hour Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Walgreens Original Anefrin Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Walgreens Extra Moisturizing Anefrin Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Walgreens 12-Hour Sinus Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex VapoSpray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Walgreens Anefrin Severe Congestion Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal D Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Rx Act Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>WinCo Foods Original Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Leader Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>12 Hour Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Mucinex Sinus-Max Moisture Smart</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>No Drip Severe Congestion Premier Value</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant Premier Value</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>No Drip Premier Value</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Clear Time</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant Extra Moisturizing Premier Value</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>SinuFrin NeilMed</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>DG Health Clear Time</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Rx Act Nasal Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Breaze Nasal Sinus Colds and Allergies</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Breaze Nasal Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>OXYMETAZOLINE HCl</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Up and up nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>WinCo Foods Extra Moisturizing Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>CVS Health Sinus Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>WinCo Foods Severe Congestion Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Assured Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasalub Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Leader Original Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Leader Extra Moisturizing Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense Nasal Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex 12 Hour Decongestant Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Visine L.R.</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>FormuCare Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin Sinus</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Zicam</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Zicam</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Mist CVS</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>EQUALINE Oxymetazoline HCl Nasal Decongestant No Drip</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Health Mart Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sinus Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark no drip</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sinus Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Leader Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Cleartime</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Anefrin Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Anefrin Nasal Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin No Drip Sinus Pump Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Good Neighbor Pharmacy Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Rexall Sinus Nasal Pump Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>OXYMETAZOLINE HCl</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Up and Up Nasal Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks QlearQuil 12 Hour Decongestant Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex 12 Hour Decongestant Ultra Fine Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex 12 Hour Decongestant Ultra Fine Mist Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Leader Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Leader Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense sinus relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Ultra Fine Mist Premier Value</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Original No Drip Nasal Walgreens</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sinus relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Sinus Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Rx Act Nasal Sinus</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>12 Hour Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Severe Congestion Nasal no drip Walgreens</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Extra Moisturizing No Drip Nasal Walgreens</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant Sinus Premier Value</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>CVS Health Nasal Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal D</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal D</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Dg Health Sinus Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Maximum Strenth Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Family Care Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Family Care Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Mist CVS</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Relief Rite Aid</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Mist Walgreens</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Original No Drip Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Max Str.Nasal Relief Severe Congestion</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex Severe No Drip</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nostrilla</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Care One Nasal Sinus</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Good Sense Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Rhofade</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Sinus</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>HEB Nasal decongestant No Drip Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>DG health sinus severe</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Maximum Strength Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>No Drip Nasal Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>No Drip Severe Nasal Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Kovanaze</name>
      <ingredients>Oxymetazoline + Tetracaine</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Clear Time</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Equate Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>No Drip</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Good Neighbor Pharmacy Nasal Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Being Well Nasal 12 Hour</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>ShopRite Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Preferred Plus Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Dristan 12 Hr</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex Severe Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Signature Care Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymethazoline HCL</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Quality Choice</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Basic Care Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Quality Choice Maximum Strength</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymetazoline Hydrochloride 12-Hour</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sound Body Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal 12 Hour</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Quality Choice Nasal Maximum Strength</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Quality Choice Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Quality Choice Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Assured Severe Congestion Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>No Drip Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>CVS Health Sinus</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Signature Care Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>No More Nosebleed</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin No Drip Original Pump Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin No Drip Severe Congestion</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin No Drip Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Marc Glassman Maximum Strength</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Assured Nasal Relief Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Best Choice</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Best Choice Allergy Sinus</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Best Choice Ultra Fine Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Best Choice</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Best Choice Maximum Strength</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Best Choice Maximum Strength</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex 12 Hour Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymetazoline HCl</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex 12 Hour Nasal Decongestant Ultra Fine Mist Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex 12 Hour Decongestant Ultra Fine Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>No Drip Nasal Mist Nasal Decongestant Severe Congestion</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Publix Maximum Strength</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Publix Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Publix</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Discount Drug Mart Maximum Strength Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Discount Drug Mart Severe Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Discount drug mart Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Discount Drug Mart Original Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Discount Drug Mart Severe Congestion Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Basic Care No Drip Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>MUCINEX Childrens Stuffy Nose</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Major</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>CVS Health</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>ShopRite Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>CVS Health No Drip</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>AVON HeXashield Congestion Relief Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymethazoline HCL</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Health Mart Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Mucinex Sinus-Max Full Force</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Health Mart Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>CVS Health No Drip</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>CVS Health Ultra Fine Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>7 Select Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>MUCINEX SINUS-MAX SEVERE CONGESTION RELIEF SINUS and ALLERGY</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>MUCINEX SINUS-MAX SEVERE NASAL CONGESTION RELIEF CLEAR and COOL NASAL</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Extra Moisturizing Nasal Pump Mist Anti Drip</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>ORIGINAL Nasal PUMP MIST No Drip</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Severe Congestion Nasal Anti-Drip Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Equaline Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Equaline Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>12 Hour Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Decongestant Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>SinuFrin Plus NeilMed</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin No Drip Original Pump Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin No Drip Severe Congestion</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin No Drip Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>12 Hour Original Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>7 Select Original Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sound Body Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Circle K Congestion Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Mucinex Nasal Moisture Smart</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Equate Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin Original Pump Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin Severe Congestion</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Mucinex Moisture Smart</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin No-Drip Allergy Sinus</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Mucinex Full Force</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Good Neighbor Pharmacy Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Mucinex Sinus-Max Full Force</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Good Neighbor Pharmacy Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Congestion Relief Lil Drug Store Products</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymetazoline HCl</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Good Neighbor Pharmacy Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Anefrin Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Sinus Severe</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Sinus Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Rhofade</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal 12 Hour</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>DG Health Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Dg Health Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Exchange Select Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Exchange Select Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Care One Nasal Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Care One Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Family Care Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Good Sense Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>CareOne Severe Congestion Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Family Care Nasal Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense Pump Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Good Sense Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Care One Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Healthy Accents Nasal Original</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Healthy Accents Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Good Sense Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Equaline Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense pump mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Preferred Plus Nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Up and Up nasal</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex Scent Free</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Signature Care Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Signature Care Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>12 Hour Original Nasal Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Long Lasting Nasal Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nafrine Pediatric Nasal Spray/drops 0.025%</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Visine L.R. Ophthalmic Sol 0.025%</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Ocuclear Oph Dps 0.025%</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Long Lasting Nasal Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Claritin Eye Allergy Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Afrin Cold</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Zicam Sinus Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Zicam Congestion Relief</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Mucinex Sinus-action Moisture Smart Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Mucinex Sinus-action Congestion &amp; Sinus Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Original Unscented Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Long Lasting Dristan Nasal Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Visine Workplace</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sinex Scent Free Ultra Fine Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sinex Original Ultra Fine Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sinex Complete</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sinex Moisturizing Ultra Fine Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Long Lasting Dristan Mentholated Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sinufrin</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sinufrin Plus</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Cooling Menthol Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Extra Moisturizing Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Congestion Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Extra Moisturizing Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Cooling Menthol Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Nasal Congestion Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Otrivin Medicated Sinus</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Otrivin Medicated No Drip</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Claritin Allergy Decongestant</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Drixoral No Drip Extra Moisturizing</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Drixoral No Drip Original Unscented</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Drixoral No Drip Cooling Menthol</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Drixoral No Drip With Calming Chamomile</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Drixoral Nasal Congestion</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Vicks Sinex Decongestant Nasal Spray 0.05%</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Long Lasting Nasal Mist</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Drixoral Decongestant Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Decongestant Nasal Mist Long Lasting</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymetazoline Hydrochloride Nasal Spray 0.05% With Moisturizers</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Oxymetazoline Hydrochloride Nasal Spray 0.05%</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Clirol Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Sbeb - Oxymetazoline Hydrochloride Nasal Solution USP, 0.05%</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Long Lasting Decongestant Nasal Spray</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Aesb - Oxymetazoline Hydrochloride Nasal Solution USP, 0.025%</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
    <mixture>
      <name>Ydyb - Oxymetazoline Hydrochloride Nasal Solution USP, 0.025%</name>
      <ingredients>Oxymetazoline</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Altaire Pharmaceuticals</name>
      <url>http://www.otcdruggist.com/index.html</url>
    </packager>
    <packager>
      <name>Bayer Healthcare</name>
      <url>http://www.bayerhealthcare.com</url>
    </packager>
    <packager>
      <name>Chain Drug</name>
      <url>http://www.chaindrug.com</url>
    </packager>
    <packager>
      <name>CVS Pharmacy</name>
      <url>http://www.cvs.com</url>
    </packager>
    <packager>
      <name>Palmetto Pharmaceuticals Inc.</name>
      <url>http://www.palmettopharm.com</url>
    </packager>
    <packager>
      <name>Perrigo Co.</name>
      <url>http://www.perrigo.com</url>
    </packager>
    <packager>
      <name>Pfizer Inc.</name>
      <url>http://www.pfizer.com</url>
    </packager>
    <packager>
      <name>S&amp;P Healthcare</name>
      <url/>
    </packager>
    <packager>
      <name>Spectrum Pharmaceuticals</name>
      <url>http://www.spectrumpharm.com</url>
    </packager>
    <packager>
      <name>Target Corp.</name>
      <url>http://www.target.com</url>
    </packager>
    <packager>
      <name>Walgreen Co.</name>
      <url>http://www.walgreens.com</url>
    </packager>
    <packager>
      <name>Wyeth Pharmaceuticals</name>
      <url>http://www.wyeth.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Schering plough healthcare products inc</manufacturer>
    <manufacturer generic="false" url="">Johnson and johnson group consumer companies</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Oxymetazoline hcl powder</description>
      <cost currency="USD">84.42</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Nasal decongestant 0.05% spray</description>
      <cost currency="USD">0.03</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Pv nasal spray 0.05%</description>
      <cost currency="USD">0.03</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Nasal spray 0.05%</description>
      <cost currency="USD">0.06</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Sinus nasal spray</description>
      <cost currency="USD">0.06</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>No drip 0.05% nasal spray</description>
      <cost currency="USD">0.13</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>CVS Pharmacy nasal spray 0.05%</description>
      <cost currency="USD">0.22</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Dristan cold multi-symp tablet</description>
      <cost currency="USD">0.23</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ocuclear eye drops</description>
      <cost currency="USD">0.23</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>12 hour nasal relief spray</description>
      <cost currency="USD">0.24</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Visine long lasting eye drops</description>
      <cost currency="USD">0.27</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Neo-synephrine 12 hour spray</description>
      <cost currency="USD">0.28</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Dristan long lasting mist</description>
      <cost currency="USD">0.32</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Afrin sinus spray</description>
      <cost currency="USD">0.33</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Anefrin 0.05% nasal spray</description>
      <cost currency="USD">0.37</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Afrin no drip sinus pump mist</description>
      <cost currency="USD">0.38</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Oxymetazoline 0.05% spray</description>
      <cost currency="USD">0.38</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Drixoral cold &amp; allergy tablet sa</description>
      <cost currency="USD">0.4</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Afrin 0.05% nose spray</description>
      <cost currency="USD">0.62</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adrenergic Agents</category>
      <mesh-id>D018663</mesh-id>
    </category>
    <category>
      <category>Adrenergic Agonists</category>
      <mesh-id>D000322</mesh-id>
    </category>
    <category>
      <category>Adrenergic alpha-1 Receptor Agonists</category>
      <mesh-id>D058646</mesh-id>
    </category>
    <category>
      <category>Adrenergic alpha-2 Receptor Agonists</category>
      <mesh-id>D058647</mesh-id>
    </category>
    <category>
      <category>Adrenergic alpha-Agonists</category>
      <mesh-id>D000316</mesh-id>
    </category>
    <category>
      <category>Agents producing tachycardia</category>
      <mesh-id/>
    </category>
    <category>
      <category>Agents that produce hypertension</category>
      <mesh-id/>
    </category>
    <category>
      <category>Autonomic Agents</category>
      <mesh-id>D001337</mesh-id>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Decongestants and Antiallergics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Imidazoles</category>
      <mesh-id>D007093</mesh-id>
    </category>
    <category>
      <category>Increased Sympathetic Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nasal Decongestants</category>
      <mesh-id>D014663</mesh-id>
    </category>
    <category>
      <category>Nasal Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Ophthalmologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Respiratory System Agents</category>
      <mesh-id>D019141</mesh-id>
    </category>
    <category>
      <category>Sensory Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sympathomimetics</category>
      <mesh-id>D013566</mesh-id>
    </category>
    <category>
      <category>Sympathomimetics Used as Decongestants</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sympathomimetics, Plain</category>
      <mesh-id/>
    </category>
    <category>
      <category>Vasoconstriction</category>
      <mesh-id>D014661</mesh-id>
    </category>
    <category>
      <category>Vasoconstrictor Agents</category>
      <mesh-id>D014662</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Spray</form>
      <route>Topical</route>
      <strength>0.05 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>0.05 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>0.05 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.05 mg/100mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.2 mg/0.4mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.05 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.00050 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.05 mg/100mg</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Nasal</route>
      <strength>50 mg/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Nasal</route>
      <strength>0.05 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Nasal</route>
      <strength>0.05 mg/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution / drops; spray</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength>0.05 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>5 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Nasal</route>
      <strength>0.05 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Topical</route>
      <strength>0.05 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.05 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>0.0005 mL/100mL</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>0.05 mg/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Oral</route>
      <strength>0.5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>0.2 mg/0.4mL</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>0.5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.05 mg/1</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>50.0 mg/100.0mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>50 mg/100mL</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>1 g/100g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>10 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>7.5 mg/15mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.05 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.512 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.0005 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.0005055 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.0005095 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>0.000512 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Ophthalmic</route>
      <strength>0.25 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>.005 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>.05 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>.5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="S01GA04">
      <level code="S01GA">Sympathomimetics used as decongestants</level>
      <level code="S01G">DECONGESTANTS AND ANTIALLERGICS</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="R01AB07">
      <level code="R01AB">Sympathomimetics, combinations excl. corticosteroids</level>
      <level code="R01A">DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE</level>
      <level code="R01">NASAL PREPARATIONS</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
    <atc-code code="R01AA05">
      <level code="R01AA">Sympathomimetics, plain</level>
      <level code="R01A">DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE</level>
      <level code="R01">NASAL PREPARATIONS</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:32.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00935.pdf?1265922744</msds>
  <patents>
    <patent>
      <number>8580282</number>
      <country>United States</country>
      <approved>2013-11-12</approved>
      <expires>2030-04-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6413499</number>
      <country>United States</country>
      <approved>2002-07-02</approved>
      <expires>2020-03-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9308191</number>
      <country>United States</country>
      <approved>2016-04-12</approved>
      <expires>2030-04-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8883838</number>
      <country>United States</country>
      <approved>2014-11-11</approved>
      <expires>2031-12-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7812049</number>
      <country>United States</country>
      <approved>2010-10-12</approved>
      <expires>2028-05-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8420688</number>
      <country>United States</country>
      <approved>2013-04-16</approved>
      <expires>2024-08-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9974773</number>
      <country>United States</country>
      <approved>2018-05-22</approved>
      <expires>2035-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8815929</number>
      <country>United States</country>
      <approved>2014-08-26</approved>
      <expires>2024-01-22</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10335391</number>
      <country>United States</country>
      <approved>2019-07-02</approved>
      <expires>2035-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Valsartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Ramipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Reserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00212</drugbank-id>
      <name>Remikiren</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Remikiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Olmesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Nitroprusside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Minoxidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Treprostinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Nisoldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Bendroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Fosinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Trandolapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Lercanidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Benazepril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Bosentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Cyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00616</drugbank-id>
      <name>Candoxatril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Candoxatril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Losartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Moexipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Eplerenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Lisinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Nitroglycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Metyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Hydroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00785</drugbank-id>
      <name>Cryptenamine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Cryptenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Perindopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Candesartan cilexetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Fenoldopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Tadalafil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Eprosartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Quinapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Methyldopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Trichlormethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Irbesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01089</drugbank-id>
      <name>Deserpidine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Deserpidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Diazoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Hydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Polythiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Saprisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Spirapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Tienilic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Debrisoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Sitaxentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Ambrisentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06445</drugbank-id>
      <name>Diethylnorspermine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Diethylnorspermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06762</drugbank-id>
      <name>Pinacidil</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Pinacidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Temocapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Riociguat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Macitentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Aliskiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Nicorandil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Efonidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09363</drugbank-id>
      <name>Rauwolfia serpentina root</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Rauwolfia serpentina root.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Enalaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Selexipag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11720</drugbank-id>
      <name>Angiotensin 1-7</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Angiotensin 1-7.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Imidapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12054</drugbank-id>
      <name>BQ-123</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of BQ-123.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Ketanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Cicletanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Dihydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Zofenopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13211</drugbank-id>
      <name>Guanoxan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Guanoxan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Delapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Vincamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Linsidomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13410</drugbank-id>
      <name>Guanoxabenz</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Guanoxabenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13429</drugbank-id>
      <name>Tolonidine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Tolonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13435</drugbank-id>
      <name>Endralazine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Endralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13452</drugbank-id>
      <name>Cadralazine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Cadralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Cyclopenthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13575</drugbank-id>
      <name>Bietaserpine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Bietaserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13604</drugbank-id>
      <name>Guanazodine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Guanazodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13631</drugbank-id>
      <name>Methoserpidine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Methoserpidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13779</drugbank-id>
      <name>Guanoclor</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Guanoclor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Muzolimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Xipamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Benazeprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Fosinoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Ramiprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Perindoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Quinaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>Felodipine may decrease the antihypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>The risk or severity of hypertension can be increased when Atomoxetine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of hypertension can be increased when Linezolid is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00895</drugbank-id>
      <name>Benzylpenicilloyl polylysine</name>
      <description>Oxymetazoline may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>The risk or severity of hypertension can be increased when Desmopressin is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of hypertension can be increased when Cyclosporine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of hypertension can be increased when Icosapent is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The risk or severity of hypertension can be increased when Eletriptan is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00217</drugbank-id>
      <name>Bethanidine</name>
      <description>The risk or severity of hypertension can be increased when Bethanidine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00221</drugbank-id>
      <name>Isoetharine</name>
      <description>The risk or severity of hypertension can be increased when Isoetharine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>The risk or severity of hypertension can be increased when Enflurane is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of hypertension can be increased when Mesalazine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>The risk or severity of hypertension can be increased when Etomidate is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The risk or severity of hypertension can be increased when Zolmitriptan is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of hypertension can be increased when Indomethacin is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of hypertension can be increased when Nabumetone is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of hypertension can be increased when Ketorolac is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of hypertension can be increased when Tenoxicam is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of hypertension can be increased when Celecoxib is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The risk or severity of hypertension can be increased when Buspirone is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of hypertension can be increased when Tolmetin is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of hypertension can be increased when Rofecoxib is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of hypertension can be increased when Piroxicam is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00561</drugbank-id>
      <name>Doxapram</name>
      <description>The risk or severity of hypertension can be increased when Doxapram is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The risk or severity of hypertension can be increased when Atropine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of hypertension can be increased when Fenoprofen is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The risk or severity of hypertension can be increased when Clonidine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of hypertension can be increased when Valdecoxib is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of hypertension can be increased when Diclofenac is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of hypertension can be increased when Sulindac is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The risk or severity of hypertension can be increased when Guanabenz is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The risk or severity of hypertension can be increased when Sumatriptan is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The risk or severity of hypertension can be increased when Sufentanil is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of hypertension can be increased when Flurbiprofen is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of hypertension can be increased when Etodolac is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The risk or severity of hypertension can be increased when Isoflurane is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of hypertension can be increased when Mefenamic acid is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of hypertension can be increased when Naproxen is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of hypertension can be increased when Sulfasalazine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The risk or severity of hypertension can be increased when Alfentanil is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of hypertension can be increased when Phenylbutazone is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of hypertension can be increased when Meloxicam is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of hypertension can be increased when Propofol is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of hypertension can be increased when Carprofen is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of hypertension can be increased when Diflunisal is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The risk or severity of hypertension can be increased when Omapatrilat is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The risk or severity of hypertension can be increased when Remifentanil is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00901</drugbank-id>
      <name>Bitolterol</name>
      <description>The risk or severity of hypertension can be increased when Bitolterol is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The risk or severity of hypertension can be increased when Almotriptan is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Salmeterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Naratriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Rizatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Formoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Oxaprozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Frovatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Salbutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Guanfacine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Methoxyflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01102</drugbank-id>
      <name>Arbutamine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Arbutamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01126</drugbank-id>
      <name>Dutasteride</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Dutasteride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Halothane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Rescinnamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Desflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01216</drugbank-id>
      <name>Finasteride</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Finasteride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Sevoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Arformoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01291</drugbank-id>
      <name>Pirbuterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Pirbuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01363</drugbank-id>
      <name>Ephedra sinica root</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Ephedra sinica root.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Bambuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with 4-Methoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01579</drugbank-id>
      <name>Phendimetrazine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Phendimetrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02032</drugbank-id>
      <name>1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04581</drugbank-id>
      <name>1-benzylimidazole</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with 1-benzylimidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Indacaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Cimicoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05395</drugbank-id>
      <name>Amibegron</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Amibegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05562</drugbank-id>
      <name>Naluzotan</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Naluzotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Cariprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06190</drugbank-id>
      <name>Solabegron</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Solabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Esmirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Vilazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Nitrous oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Xylometazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Dexmethylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06706</drugbank-id>
      <name>Isometheptene</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Isometheptene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06711</drugbank-id>
      <name>Naphazoline</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Naphazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06763</drugbank-id>
      <name>Saralasin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Saralasin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Felbinac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08810</drugbank-id>
      <name>Cinitapride</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Cinitapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Mirabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08925</drugbank-id>
      <name>Adrafinil</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Adrafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Ifenprodil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08957</drugbank-id>
      <name>Hexoprenaline</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Hexoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Floctafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Vortioxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Olodaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Vilanterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Benzydamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09202</drugbank-id>
      <name>Cirazoline</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Cirazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Moxisylyte.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Dexibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Firocoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09242</drugbank-id>
      <name>Moxonidine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Moxonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Morniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Talniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11278</drugbank-id>
      <name>DL-Methylephedrine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with DL-Methylephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11373</drugbank-id>
      <name>Amitraz</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Amitraz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Medetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Robenacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Xylazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11481</drugbank-id>
      <name>Atipamezole</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Atipamezole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11541</drugbank-id>
      <name>Ractopamine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Ractopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Romifidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Detomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Etafedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11738</drugbank-id>
      <name>Rilmenidine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Rilmenidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11755</drugbank-id>
      <name>Tetrahydrocannabivarin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Tetrahydrocannabivarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11871</drugbank-id>
      <name>PF-00610355</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with PF-00610355.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12100</drugbank-id>
      <name>Abediterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Abediterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12248</drugbank-id>
      <name>Tulobuterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Tulobuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12313</drugbank-id>
      <name>Dopexamine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Dopexamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12361</drugbank-id>
      <name>Piclozotan</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Piclozotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Siponimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12551</drugbank-id>
      <name>Idazoxan</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Idazoxan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Higenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12846</drugbank-id>
      <name>Reproterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Reproterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Levosalbutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Alclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Fentiazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Suxibuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13251</drugbank-id>
      <name>Octopamine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Octopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Bumadizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Alminoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Flunoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Trichloroethylene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Feprazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Difenpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13378</drugbank-id>
      <name>Norfenefrine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Norfenefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13398</drugbank-id>
      <name>Oxyfedrine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Oxyfedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Nifenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Lonazolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13453</drugbank-id>
      <name>Xenon</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Xenon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Tenidap.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Bendazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Buflomedil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Pranoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Propyphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Proglumetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Ethenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13559</drugbank-id>
      <name>Rimiterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Rimiterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Mofebutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Proquazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Benorilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Pirprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13781</drugbank-id>
      <name>Xamoterol</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Xamoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Imidazole salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14010</drugbank-id>
      <name>5-methoxy-N,N-dimethyltryptamine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with 5-methoxy-N,N-dimethyltryptamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with SC-236.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with NS-398.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14231</drugbank-id>
      <name>Quinoline Yellow WS</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Quinoline Yellow WS.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00070</drugbank-id>
      <name>Hyaluronidase (ovine)</name>
      <description>Hyaluronidase (ovine) may increase the vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Mianserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Mirtazapine may decrease the antihypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>Tedizolid phosphate may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Theophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Dyphylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pentoxifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Aminophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01303</drugbank-id>
      <name>Oxtriphylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Oxtriphylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Theobromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01482</drugbank-id>
      <name>Fenethylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Fenethylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 8-azaguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01978</drugbank-id>
      <name>7,9-Dimethylguanine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 7,9-Dimethylguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02134</drugbank-id>
      <name>Xanthine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Xanthine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02245</drugbank-id>
      <name>7-Deazaguanine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 7-Deazaguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02377</drugbank-id>
      <name>Guanine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Guanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02489</drugbank-id>
      <name>9-Methylguanine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 9-Methylguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02568</drugbank-id>
      <name>Peldesine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Peldesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04076</drugbank-id>
      <name>Hypoxanthine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Hypoxanthine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04356</drugbank-id>
      <name>9-Deazaguanine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 9-Deazaguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06479</drugbank-id>
      <name>Propentofylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Propentofylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06575</drugbank-id>
      <name>Valomaciclovir</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Valomaciclovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07954</drugbank-id>
      <name>3-isobutyl-1-methyl-7H-xanthine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3-isobutyl-1-methyl-7H-xanthine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08844</drugbank-id>
      <name>Uric acid</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Uric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Doxofylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 6-O-benzylguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lisofylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12531</drugbank-id>
      <name>Lobucavir</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lobucavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12926</drugbank-id>
      <name>Cafedrine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Cafedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13203</drugbank-id>
      <name>Bamifylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Bamifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13449</drugbank-id>
      <name>Proxyphylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Proxyphylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13573</drugbank-id>
      <name>Acefylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Acefylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13592</drugbank-id>
      <name>Etamiphylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Etamiphylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13634</drugbank-id>
      <name>Pentifylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pentifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13812</drugbank-id>
      <name>Bufylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Bufylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Bromotheophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14029</drugbank-id>
      <name>Furafylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Furafylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14132</drugbank-id>
      <name>8-chlorotheophylline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 8-chlorotheophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15122</drugbank-id>
      <name>PCS-499</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with PCS-499.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06704</drugbank-id>
      <name>Iobenguane</name>
      <description>Oxymetazoline can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Amitriptyline may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Imipramine may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Clomipramine may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Amineptine may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Dimetacrine may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Butriptyline may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Dosulepin may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Tianeptine may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Oxaprotiline may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Opipramol may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Amitriptylinoxide may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Dibenzepin may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Quinupramine may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Melitracen may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Lofepramine may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Iprindole may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Imipramine oxide may increase the vasopressor activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>Methysergide may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>Cabergoline may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00353</drugbank-id>
      <name>Methylergometrine</name>
      <description>Methylergometrine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>Lisuride may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>Ergotamine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00699</drugbank-id>
      <name>Nicergoline</name>
      <description>Nicergoline may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>Pergolide may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>Bromocriptine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>Ergometrine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic acid diethylamide</name>
      <description>Lysergic acid diethylamide may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11273</drugbank-id>
      <name>Dihydroergocornine</name>
      <description>Dihydroergocornine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13385</drugbank-id>
      <name>Dihydroergocryptine</name>
      <description>Dihydroergocryptine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13399</drugbank-id>
      <name>Terguride</name>
      <description>Terguride may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13520</drugbank-id>
      <name>Metergoline</name>
      <description>Metergoline may increase the hypertensive and vasoconstricting activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Venlafaxine may increase the tachycardic activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>Duloxetine may increase the tachycardic activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>Sibutramine may increase the tachycardic activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>Milnacipran may increase the tachycardic activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>Desvenlafaxine may increase the tachycardic activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>Levomilnacipran may increase the tachycardic activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The risk or severity of adverse effects can be increased when Phentermine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00211</drugbank-id>
      <name>Midodrine</name>
      <description>The risk or severity of adverse effects can be increased when Midodrine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00388</drugbank-id>
      <name>Phenylephrine</name>
      <description>The risk or severity of adverse effects can be increased when Phenylephrine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00397</drugbank-id>
      <name>Phenylpropanolamine</name>
      <description>The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00610</drugbank-id>
      <name>Metaraminol</name>
      <description>The risk or severity of adverse effects can be increased when Metaraminol is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00723</drugbank-id>
      <name>Methoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Methoxamine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00816</drugbank-id>
      <name>Orciprenaline</name>
      <description>The risk or severity of adverse effects can be increased when Orciprenaline is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00830</drugbank-id>
      <name>Phenmetrazine</name>
      <description>The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>The risk or severity of adverse effects can be increased when Dobutamine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Benzphetamine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00867</drugbank-id>
      <name>Ritodrine</name>
      <description>The risk or severity of adverse effects can be increased when Ritodrine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The risk or severity of adverse effects can be increased when Terbutaline is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Diethylpropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Dopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01064</drugbank-id>
      <name>Isoprenaline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lisdexamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Fenoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Ephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mephentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01366</drugbank-id>
      <name>Procaterol</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Procaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Clenbuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with MMDA.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Midomafetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 2,5-Dimethoxy-4-ethylamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 4-Bromo-2,5-dimethoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tenamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Chlorphentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Methylenedioxyethamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Dextroamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Metamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Nylidrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06764</drugbank-id>
      <name>Tetryzoline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tetryzoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08841</drugbank-id>
      <name>Tyramine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Isoxsuprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08985</drugbank-id>
      <name>Etilefrine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Etilefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09203</drugbank-id>
      <name>Synephrine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Synephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Iofetamine I-123.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Ritobegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13064</drugbank-id>
      <name>Tramazoline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tramazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mephedrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13341</drugbank-id>
      <name>Fenozolone</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Fenozolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Methoxyphenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13692</drugbank-id>
      <name>Tretoquinol</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tretoquinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Gepefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13777</drugbank-id>
      <name>Prenalterol</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Prenalterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13852</drugbank-id>
      <name>Mefenorex</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mefenorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>The risk or severity of Tachycardia can be increased when Dronabinol is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>The risk or severity of Tachycardia can be increased when Nabilone is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05077</drugbank-id>
      <name>SLV319</name>
      <description>The risk or severity of Tachycardia can be increased when SLV319 is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05372</drugbank-id>
      <name>CP-945598</name>
      <description>The risk or severity of Tachycardia can be increased when CP-945598 is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06155</drugbank-id>
      <name>Rimonabant</name>
      <description>The risk or severity of Tachycardia can be increased when Rimonabant is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06624</drugbank-id>
      <name>Taranabant</name>
      <description>The risk or severity of Tachycardia can be increased when Taranabant is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The risk or severity of Tachycardia can be increased when Cannabidiol is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11903</drugbank-id>
      <name>GW842166</name>
      <description>The risk or severity of Tachycardia can be increased when GW842166 is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12193</drugbank-id>
      <name>Ajulemic acid</name>
      <description>The risk or severity of Tachycardia can be increased when Ajulemic acid is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12649</drugbank-id>
      <name>Ibipinabant</name>
      <description>The risk or severity of Tachycardia can be increased when Ibipinabant is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13070</drugbank-id>
      <name>Surinabant</name>
      <description>The risk or severity of Tachycardia can be increased when Surinabant is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The risk or severity of Tachycardia can be increased when Nabiximols is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14043</drugbank-id>
      <name>Palmidrol</name>
      <description>The risk or severity of Tachycardia can be increased when Palmidrol is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14737</drugbank-id>
      <name>Cannabinol</name>
      <description>The risk or severity of Tachycardia can be increased when Cannabinol is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Alfuzosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Droperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Prazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Doxazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Phentolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Tamsulosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propiomazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00797</drugbank-id>
      <name>Tolazoline</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Tolazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00925</drugbank-id>
      <name>Phenoxybenzamine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Phenoxybenzamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Terazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Periciazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Thioproperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Silodosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08950</drugbank-id>
      <name>Indoramin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Indoramin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09206</drugbank-id>
      <name>Trimazosin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trimazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12230</drugbank-id>
      <name>Bunazosin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bunazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propiverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Urapidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Amphetamine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Furazolidone may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>Procaine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minaprine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>Selegiline may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>Procarbazine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Moclobemide may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Isocarboxazid may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Rasagiline may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Pargyline may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>Clorgiline may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Iproniazid may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Nialamide may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Safinamide may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Hydracarbazine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Pirlindole may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Toloxatone may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Benmoxin may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Mebanazine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Octamoxin may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Pheniprazine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Phenoxypropazine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Pivhydrazine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Safrazine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Caroxazone may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>Harmaline may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>Brofaromine may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>The risk or severity of hypotension can be increased when Patent Blue is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Dexpropranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Befunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Levobetaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Anisodamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Landiolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Mepindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Tertatolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be increased when used in combination with Norepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be increased when used in combination with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>The therapeutic efficacy of Oxymetazoline can be increased when used in combination with Droxidopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06707</drugbank-id>
      <name>Levonordefrin</name>
      <description>The therapeutic efficacy of Oxymetazoline can be increased when used in combination with Levonordefrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06814</drugbank-id>
      <name>Protokylol</name>
      <description>The therapeutic efficacy of Oxymetazoline can be increased when used in combination with Protokylol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11124</drugbank-id>
      <name>Racepinephrine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be increased when used in combination with Racepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The therapeutic efficacy of Oxymetazoline can be increased when used in combination with Theodrenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be increased when used in combination with Ibopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13917</drugbank-id>
      <name>Deoxyepinephrine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be increased when used in combination with Deoxyepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00226</drugbank-id>
      <name>Guanadrel</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Guanadrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Profenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bretylium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Guanethidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12057</drugbank-id>
      <name>ORM-12741</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with ORM-12741.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The risk or severity of Tachycardia can be increased when Nicotine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The risk or severity of Tachycardia can be increased when Tramadol is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The risk or severity of Tachycardia can be increased when Trospium is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The risk or severity of Tachycardia can be increased when Benzatropine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of Tachycardia can be increased when Anagrelide is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of Tachycardia can be increased when Disopyramide is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>The risk or severity of Tachycardia can be increased when Ipratropium is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The risk or severity of Tachycardia can be increased when Metixene is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The risk or severity of Tachycardia can be increased when Buclizine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The risk or severity of Tachycardia can be increased when Doxylamine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The risk or severity of Tachycardia can be increased when Procyclidine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The risk or severity of Tachycardia can be increased when Cyproheptadine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>The risk or severity of Tachycardia can be increased when Methscopolamine bromide is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The risk or severity of Tachycardia can be increased when Gallamine triethiodide is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The risk or severity of Tachycardia can be increased when Darifenacin is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The risk or severity of Tachycardia can be increased when Triflupromazine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>The risk or severity of Tachycardia can be increased when Anisotropine methylbromide is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of Tachycardia can be increased when Lamotrigine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00640</drugbank-id>
      <name>Adenosine</name>
      <description>The risk or severity of Tachycardia can be increased when Adenosine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The risk or severity of Tachycardia can be increased when Pirenzepine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The risk or severity of Tachycardia can be increased when Paroxetine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The risk or severity of Tachycardia can be increased when Rocuronium is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The risk or severity of Tachycardia can be increased when Scopolamine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The risk or severity of Tachycardia can be increased when Benzquinamide is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The risk or severity of Tachycardia can be increased when Clidinium is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The risk or severity of Tachycardia can be increased when Propantheline is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The risk or severity of Tachycardia can be increased when Dicyclomine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The risk or severity of Tachycardia can be increased when Biperiden is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The risk or severity of Tachycardia can be increased when Brompheniramine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The risk or severity of Tachycardia can be increased when Cocaine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The risk or severity of Tachycardia can be increased when Maprotiline is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Cycrimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Glycopyrronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Tolterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Flavoxate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Cilostazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Ketamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Diphenidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Isopropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Mepenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Fesoterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Hexocyclium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Dimetindene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Aclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Dexetimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Chlorphenoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Umeclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Trimebutine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Imidafenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Butylscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Thonzylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Methscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Oxitropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Tropatepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Prifinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Piperidolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Benzilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Difemerine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Phenglutarimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Mazaticol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Etybenzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Emepronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Poldine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Bevonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Rociverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Bornaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Etanautine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Tiemonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Dihexyverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Penthienate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Diphemanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Camylofin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Fenpiverinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Emetonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Pipenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Timepidium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Medical Cannabis.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Salmon Calcitonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Thyrotropin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00066</drugbank-id>
      <name>Follitropin</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Liothyronine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Carbimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Levothyroxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Propylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Liotrix.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03374</drugbank-id>
      <name>3,5-Diiodotyrosine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3,5-Diiodotyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tiratricol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05084</drugbank-id>
      <name>Abaloparatide</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Abaloparatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05829</drugbank-id>
      <name>Parathyroid hormone</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06285</drugbank-id>
      <name>Teriparatide</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Teriparatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06715</drugbank-id>
      <name>Potassium Iodide</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Potassium Iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07637</drugbank-id>
      <name>Dibromotyrosine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Dibromotyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Thyroid, porcine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Potassium perchlorate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09421</drugbank-id>
      <name>Protirelin</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Protirelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12629</drugbank-id>
      <name>3,5-diiodothyropropionic acid</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3,5-diiodothyropropionic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13644</drugbank-id>
      <name>Methylthiouracil</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Methylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13742</drugbank-id>
      <name>Elcatonin</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Elcatonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13804</drugbank-id>
      <name>Benzylthiouracil</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Benzylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15263</drugbank-id>
      <name>Thyrotropin</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Thyrotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The risk or severity of hypertension can be increased when Esketamine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>The risk or severity of hypertension can be increased when Solriamfetol is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>Testosterone undecanoate may increase the hypertensive activities of Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The risk or severity of hypertension can be increased when Oxymetazoline is combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The risk or severity of adverse effects can be increased when Tizanidine is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>Oxymetazoline can cause a decrease in the absorption of Fentanyl resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The therapeutic efficacy of Glyburide can be decreased when used in combination with Oxymetazoline.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.15e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.03</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>oxymetazoline</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>260.3746</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>260.1888634</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C16H24N2O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>WYWIFABBXFUGLM-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>44.62</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>79.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>30.64</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>10.91</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>10.15</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>182 ¬∞C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.4</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>10195</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>7862</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>4636</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505622</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07363</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4475</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>30712</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164748840</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000235</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>124</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>124</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Oxymetazoline</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL762</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/oxymetazoline-solution.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000501</id>
      <name>Alpha-1A adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5922</ref-id>
            <pubmed-id>8894610</pubmed-id>
            <citation>Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91.</citation>
          </article>
          <article>
            <ref-id>A5923</ref-id>
            <pubmed-id>8768700</pubmed-id>
            <citation>Deplanne V, Galzin AM: Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit. J Pharmacol Exp Ther. 1996 Aug;278(2):527-34.</citation>
          </article>
          <article>
            <ref-id>A5924</ref-id>
            <pubmed-id>11774707</pubmed-id>
            <citation>Shibata K, Taketani K: [Excitatory effect of noradrenaline on rat airway parasympathetic ganglion neurons]. Fukuoka Igaku Zasshi. 2001 Nov;92(11):377-83.</citation>
          </article>
          <article>
            <ref-id>A5925</ref-id>
            <pubmed-id>8564226</pubmed-id>
            <citation>Furukawa K, Rosario DJ, Smith DJ, Chapple CR, Uchiyama T, Chess-Williams R: Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol. 1995 Sep;116(1):1605-10.</citation>
          </article>
          <article>
            <ref-id>A5926</ref-id>
            <pubmed-id>11527538</pubmed-id>
            <citation>Gonzalez-Espinosa C, Romero-Avila MT, Mora-Rodriguez DM, Gonzalez-Espinosa D, Garcia-Sainz JA: Molecular cloning and functional expression of the guinea pig alpha(1a)-adrenoceptor. Eur J Pharmacol. 2001 Aug 31;426(3):147-55.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P35348" source="Swiss-Prot">
        <name>Alpha-1A adrenergic receptor</name>
        <general-function>Protein heterodimerization activity</general-function>
        <specific-function>This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.</specific-function>
        <gene-name>ADRA1A</gene-name>
        <locus>8p21-p11.2</locus>
        <cellular-location>Nucleus membrane</cellular-location>
        <transmembrane-regions>28-51
65-88
100-122
144-167
182-205
274-297
306-329</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.23</theoretical-pi>
        <molecular-weight>51486.005</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:277</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA1A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D25235</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>433201</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>22</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>22</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35348</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA1A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRA1C</synonym>
          <synonym>Alpha-1A adrenoceptor</synonym>
          <synonym>Alpha-1A adrenoreceptor</synonym>
          <synonym>Alpha-1C adrenergic receptor</synonym>
          <synonym>Alpha-adrenergic receptor 1c</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001000|Alpha-1A adrenergic receptor
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSV
THYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCII
SIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINE
EPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKN
APAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPD
FKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTL
HPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCT
TARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010352|Alpha-1A adrenergic receptor (ADRA1A)
ATGGTGTTTCTCTCGGGAAATGCTTCCGACAGCTCCAACTGCACCCAACCGCCGGCACCG
GTGAACATTTCCAAGGCCATTCTGCTCGGGGTGATCTTGGGGGGCCTCATTCTTTTCGGG
GTGCTGGGTAACATCCTAGTGATCCTCTCCGTAGCCTGTCACCGACACCTGCACTCAGTC
ACGCACTACTACATCGTCAACCTGGCGGTGGCCGACCTCCTGCTCACCTCCACGGTGCTG
CCCTTCTCCGCCATCTTCGAGGTCCTAGGCTACTGGGCCTTCGGCAGGGTCTTCTGCAAC
ATCTGGGCGGCAGTGGATGTGCTGTGCTGCACCGCGTCCATCATGGGCCTCTGCATCATC
TCCATCGACCGCTACATCGGCGTGAGCTACCCGCTGCGCTACCCAACCATCGTCACCCAG
AGGAGGGGTCTCATGGCTCTGCTCTGCGTCTGGGCACTCTCCCTGGTCATATCCATTGGA
CCCCTGTTCGGCTGGAGGCAGCCGGCCCCCGAGGACGAGACCATCTGCCAGATCAACGAG
GAGCCGGGCTACGTGCTCTTCTCAGCGCTGGGCTCCTTCTACCTGCCTCTGGCCATCATC
CTGGTCATGTACTGCCGCGTCTACGTGGTGGCCAAGAGGGAGAGCCGGGGCCTCAAGTCT
GGCCTCAAGACCGACAAGTCGGACTCGGAGCAAGTGACGCTCCGCATCCATCGGAAAAAC
GCCCCGGCAGGAGGCAGCGGGATGGCCAGCGCCAAGACCAAGACGCACTTCTCAGTGAGG
CTCCTCAAGTTCTCCCGGGAGAAGAAAGCGGCCAAAACGCTGGGCATCGTGGTCGGCTGC
TTCGTCCTCTGCTGGCTGCCTTTTTTCTTAGTCATGCCCATTGGGTCTTTCTTCCCTGAT
TTCAAGCCCTCTGAAACAGTTTTTAAAATAGTATTTTGGCTCGGATATCTAAACAGCTGC
ATCAACCCCATCATATACCCATGCTCCAGCCAAGAGTTCAAAAAGGCCTTTCAGAATGTC
TTGAGAATCCAGTGTCTCTGCAGAAAGCAGTCTTCCAAACATGCCCTGGGCTACACCCTG
CACCCGCCCAGCCAGGCCGTGGAAGGGCAACACAAGGACATGGTGCGCATCCCCGTGGGA
TCAAGAGAGACCTTCTACAGGATCTCCAAGACGGATGGCGTTTGTGAATGGAAATTTTTC
TCTTCCATGCCCCGTGGATCTGCCAGGATTACAGTGTCCAAAGACCAATCCTCCTGTACC
ACAGCCCGGGTGAGAAGTAAAAGCTTTTTGCAGGTCTGCTGCTGTGTAGGGCCCTCAACC
CCCAGCCTTGACAAGAACCATCAAGTTCCAACCATTAAGGTCCACACCATCTCCCTCAGT
GAGAACGGGGAGGAAGTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha1-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of Rho protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein kinase C signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of synaptic transmission, GABAergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle contraction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0000289</id>
      <name>Alpha-2A adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A10978</ref-id>
            <pubmed-id>1327384</pubmed-id>
            <citation>MacKinnon AC, Kilpatrick AT, Kenny BA, Spedding M, Brown CM: [3H]-RS-15385-197, a selective and high affinity radioligand for alpha 2-adrenoceptors: implications for receptor classification. Br J Pharmacol. 1992 Aug;106(4):1011-8.</citation>
          </article>
          <article>
            <ref-id>A10979</ref-id>
            <pubmed-id>17164433</pubmed-id>
            <citation>Mitrani P, Srinivasan M, Dodds C, Patel MS: Role of the autonomic nervous system in the development of hyperinsulinemia by high-carbohydrate formula feeding to neonatal rats. Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1069-78. Epub 2006 Dec 12.</citation>
          </article>
          <article>
            <ref-id>A10980</ref-id>
            <pubmed-id>7892112</pubmed-id>
            <citation>Lepretre N, Mironneau J: Alpha 2-adrenoceptors activate dihydropyridine-sensitive calcium channels via Gi-proteins and protein kinase C in rat portal vein myocytes. Pflugers Arch. 1994 Dec;429(2):253-61.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P08913" source="Swiss-Prot">
        <name>Alpha-2A adrenergic receptor</name>
        <general-function>Thioesterase binding</general-function>
        <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline &gt; clonidine &gt; epinephrine &gt; norepinephrine &gt; phenylephrine &gt; dopamine &gt; p-synephrine &gt; p-tyramine &gt; serotonin = p-octopamine. For antagonists, the rank order is yohimbine &gt; phentolamine = mianserine &gt; chlorpromazine = spiperone = prazosin &gt; propanolol &gt; alprenolol = pindolol.</specific-function>
        <gene-name>ADRA2A</gene-name>
        <locus>10q24-q26</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>34-59
71-96
107-129
152-172
195-217
375-395
410-429</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>10.2</theoretical-pi>
        <molecular-weight>48956.275</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:281</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA2A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M23533</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178196</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>25</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>25</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08913</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA2A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRA2R</synonym>
          <synonym>ADRAR</synonym>
          <synonym>Alpha-2 adrenergic receptor subtype C10</synonym>
          <synonym>Alpha-2A adrenoceptor</synonym>
          <synonym>Alpha-2A adrenoreceptor</synonym>
          <synonym>Alpha-2AAR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021255|Alpha-2A adrenergic receptor
MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT
SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS
IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG
PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA
APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD
HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS
RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS
LNPVIYTIFNHDFRRAFKKILCRGDRKRIV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021256|Alpha-2A adrenergic receptor (ADRA2A)
ATGTTCCGCCAGGAGCAGCCGTTGGCCGAGGGCAGCTTTGCGCCCATGGGCTCCCTGCAG
CCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCGGCGCCCGGGCC
ACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCCTGCTCATGCTG
CTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCCGCGCGCTCAAG
GCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGGTGGCCACGCTC
GTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCGGCAAGGCTTGG
TGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCGTGCACCTGTGC
GCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAGTACAACCTGAAGCGC
ACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGGCCGTCATCTCC
TTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGCAGCCGGCCGAG
CCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGCATCGGCTCCTTC
TTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGATCGCCAAGCGT
CGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCGCCGCCGGGGGGC
ACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCCGGGGGGCGCAGAG
GCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCGCGCCGGCCGGGCCG
CGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGACCACGCCGAGCGGCCT
CCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAGGCCCGAGCGAGCCAG
GTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCGACGGGGATCGGGACGCCG
GCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGCGCTGGCGCGGGCGG
CAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATCGGAGTGTTCGTGGTG
TGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGGTGCTCCGTGCCACGC
ACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCGTTGAACCCGGTCATC
TACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATCCTCTGTCGGGGGGAC
AGGAAGCGGATCGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-1B adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-2C adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha2-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heterotrimeric G-protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>norepinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thioesterase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>actin cytoskeleton organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase B activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestinal absorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>movement of cell or subcellular component</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion-dependent exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion involved in cellular response to glucose stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of norepinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of uterine smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epidermal growth factor-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of membrane protein ectodomain proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasodilation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of wound healing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Rho protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thermoception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="1">
      <id>BE0000342</id>
      <name>Alpha-2C adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6969</ref-id>
            <pubmed-id>20030735</pubmed-id>
            <citation>Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P18825" source="Swiss-Prot">
        <name>Alpha-2C adrenergic receptor</name>
        <general-function>Protein homodimerization activity</general-function>
        <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.</specific-function>
        <gene-name>ADRA2C</gene-name>
        <locus>4p16</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>52-76
89-114
125-147
169-191
208-231
380-407
421-441</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>10.69</theoretical-pi>
        <molecular-weight>49521.585</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:283</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA2C</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J03853</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178194</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>27</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>27</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P18825</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA2C_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRA2L2</synonym>
          <synonym>ADRA2RL2</synonym>
          <synonym>Alpha-2 adrenergic receptor subtype C4</synonym>
          <synonym>Alpha-2C adrenoceptor</synonym>
          <synonym>Alpha-2C adrenoreceptor</synonym>
          <synonym>Alpha-2CAR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000681|Alpha-2C adrenergic receptor
MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGF
LIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFG
QVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISA
VISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLR
TRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGA
LRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRR
RRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFK
FFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010255|Alpha-2C adrenergic receptor (ADRA2C)
ATGGCGTCCCCGGCGCTGGCGGCGGCGCTGGCGGTGGCGGCAGCGGCGGGCCCCAATGCG
AGCGGCGCGGGCGAGAGGGGCAGCGGCGGGGTTGCCAATGCCTCGGGGGCTTCCTGGGGG
CCGCCGCGCGGCCAGTACTCGGCGGGCGCGGTGGCAGGGCTGGCTGCCGTGGTGGGCTTC
CTCATCGTCTTCACCGTGGTGGGCAACGTGCTGGTGGTGATCGCCGTGCTGACCAGCCGG
GCGCTGCGCGCGCCACAGAACCTCTTCCTGGTGTCGCTGGCCTCGGCCGACATCCTGGTG
GCCACGCTGGTCATGCCCTTCTCGTTGGCCAACGAGCTCATGGCCTACTGGTACTTCGGG
CAGGTGTGGTGCGGCGTGTACCTGGCGCTCGATGTGCTGTTTTGCACCTCGTCGATCGTG
CATCTGTGTGCCATCAGCCTGGACCGCTACTGGTCGGTGACGCAGGCCGTCGAGTACAAC
CTGAAGCGCACACCACGCCGCGTCAAGGCCACCATCGTGGCCGTGTGGCTCATCTCGGCC
GTCATCTCCTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCCTACCCG
CAGTGCGGCCTCAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCTTCTTC
GCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGCCAAGCTGCGC
ACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGGTGCGTCCCCGACTACC
GAAAACGGGCTGGGCGCGGCGGCAGGCGCAGGCGAGAACGGGCACTGCGCGCCCCCGCCC
GCCGACGTGGAGCCGGACGAGAGCAGCGCAGCGGCCGAGAGGCGGCGGCGCCGGGGCGCG
TTGCGGCGGGGCGGGCGGCGGCGAGCGGGCGCGGAGGGGGGCGCGGGCGGTGCGGACGGG
CAGGGGGCGGGGCCGGGGGCGGCTGAGTCGGGGGCGCTGACCGCCTCCAGGTCCCCGGGG
CCCGGTGGCCGCCTGTCGCGCGCCAGCTCGCGCTCCGTCGAGTTCTTCCTGTCGCGCCGG
CGCCGGGCGCGCAGCAGCGTGTGCCGCCGCAAGGTGGCCCAGGCGCGCGAGAAGCGCTTC
ACCTTTGTGCTGGCTGTGGTCATGGGCGTGTTCGTGCTCTGCTGGTTCCCCTTCTTCTTC
AGCTACAGCCTGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCCCGCTCTTCAAG
TTCTTCTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACGGTCTTC
AACCAGGATTTCCGGCGATCCTTTAAGCACATCCTCTTCCGACGGAGGAGAAGGGGCTTC
AGGCAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-2A adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha2-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase B activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion involved in cellular response to glucose stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of norepinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of uterine smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000572</id>
      <name>Alpha-2B adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18273</ref-id>
            <pubmed-id>1666366</pubmed-id>
            <citation>Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43.</citation>
          </article>
          <article>
            <ref-id>A18261</ref-id>
            <pubmed-id>21948594</pubmed-id>
            <citation>Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777.  Epub 2011 Sep 23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P18089" source="Swiss-Prot">
        <name>Alpha-2B adrenergic receptor</name>
        <general-function>Epinephrine binding</general-function>
        <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine &gt; norepinephrine &gt; epinephrine = oxymetazoline &gt; dopamine &gt; p-tyramine = phenylephrine &gt; serotonin &gt; p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine &gt; chlorpromazine &gt; phentolamine &gt; mianserine &gt; spiperone &gt; prazosin &gt; alprenolol &gt; propanolol &gt; pindolol.</specific-function>
        <gene-name>ADRA2B</gene-name>
        <locus>2p13-q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>13-38
49-69
87-107
129-149
173-193
370-393
403-423</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.52</theoretical-pi>
        <molecular-weight>49565.8</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:282</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA2B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M34041</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178198</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>26</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>26</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P18089</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA2B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRA2L1</synonym>
          <synonym>ADRA2RL1</synonym>
          <synonym>Alpha-2 adrenergic receptor subtype C2</synonym>
          <synonym>Alpha-2B adrenoceptor</synonym>
          <synonym>Alpha-2B adrenoreceptor</synonym>
          <synonym>Alpha-2BAR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010396|Alpha-2B adrenergic receptor
MDHQDPYSVQATAAIAAAITFLILFTIFGNALVILAVLTSRSLRAPQNLFLVSLAAADIL
VATLIIPFSLANELLGYWYFRRTWCEVYLALDVLFCTSSIVHLCAISLDRYWAVSRALEY
NSKRTPRRIKCIILTVWLIAAVISLPPLIYKGDQGPQPRGRPQCKLNQEAWYILASSIGS
FFAPCLIMILVYLRIYLIAKRSNRRGPRAKGGPGQGESKQPRPDHGGALASAKLPALASV
ASAREVNGHSKSTGEKEEGETPEDTGTRALPPSWAALPNSGQGQKEGVCGASPEDEAEEE
EEEEEECEPQAVPVSPASACSPPLQQPQGSRVLATLRGQVLLGRGVGAIGGQWWRRRAQL
TREKRFTFVLAVVIGVFVLCWFPFFFSYSLGAICPKHCKVPHGLFQFFFWIGYCNSSLNP
VIYTIFNQDFRRAFRRILCRPWTQTAW</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010397|Alpha-2B adrenergic receptor (ADRA2B)
ATGGACCACCAGGACCCCTACTCCGTGCAGGCCACAGCGGCCATAGCGGCGGCCATCACC
TTCCTCATTCTCTTTACCATCTTCGGCAACGCTCTGGTCATCCTGGCTGTGTTGACCAGC
CGCTCGCTGCGCGCCCCTCAGAACCTGTTCCTGGTGTCGCTGGCCGCCGCCGACATCCTG
GTGGCCACGCTCATCATCCCTTTCTCGCTGGCCAACGAGCTGCTGGGCTACTGGTACTTC
CGGCGCACGTGGTGCGAGGTGTACCTGGCGCTCGACGTGCTCTTCTGCACCTCGTCCATC
GTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGGCCGTGAGCCGCGCGCTGGAGTAC
AACTCCAAGCGCACCCCGCGCCGCATCAAGTGCATCATCCTCACTGTGTGGCTCATCGCC
GCCGTCATCTCGCTGCCGCCCCTCATCTACAAGGGCGACCAGGGCCCCCAGCCGCGCGGG
CGCCCCCAGTGCAAGCTCAACCAGGAGGCCTGGTACATCCTGGCCTCCAGCATCGGATCT
TTCTTTGCTCCTTGCCTCATCATGATCCTTGTCTACCTGCGCATCTACCTGATCGCCAAA
CGCAGCAACCGCAGAGGTCCCAGGGCCAAGGGGGGGCCTGGGCAGGGTGAGTCCAAGCAG
CCCCGACCCGACCATGGTGGGGCTTTGGCCTCAGCCAAACTGCCAGCCCTGGCCTCTGTG
GCTTCTGCCAGAGAGGTCAACGGACACTCGAAGTCCACTGGGGAGAAGGAGGAGGGGGAG
ACCCCTGAAGATACTGGGACCCGGGCCTTGCCACCCAGTTGGGCTGCCCTTCCCAACTCA
GGCCAGGGCCAGAAGGAGGGTGTTTGTGGGGCATCTCCAGAGGATGAAGCTGAAGAGGAG
GAAGAGGAGGAGGAGGAGGAGGAAGAGTGTGAACCCCAGGCAGTGCCAGTGTCTCCGGCC
TCAGCTTGCAGCCCCCCGCTGCAGCAGCCACAGGGCTCCCGGGTGCTGGCCACCCTACGT
GGCCAGGTGCTCCTGGGCAGGGGCGTGGGTGCTATAGGTGGGCAGTGGTGGCGTCGACGG
GCGCAGCTGACCCGGGAGAAGCGCTTCACCTTCGTGCTGGCTGTGGTCATTGGCGTTTTT
GTGCTCTGCTGGTTCCCCTTCTTCTTCAGCTACAGCCTGGGAGCCATCTGCCCGAAGCAC
TGCAAGGTGCCCCATGGCCTCTTCCAGTTCTTCTTCTGGATCGGCTACTGCAACAGCTCA
CTGAACCCTGTTATCTACACCATCTTCAACCAGGACTTCCGCCGTGCCTTCCGGAGGATC
CTGTGCCGCCCGTGGACCCAGACGGCCTGGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha2-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase B activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of norepinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000575</id>
      <name>Alpha-1B adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6969</ref-id>
            <pubmed-id>20030735</pubmed-id>
            <citation>Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x.</citation>
          </article>
          <article>
            <ref-id>A18283</ref-id>
            <pubmed-id>23364786</pubmed-id>
            <citation>Akinaga J, Lima V, Kiguti LR, Hebeler-Barbosa F, Alcantara-Hernandez R, Garcia-Sainz JA, Pupo AS: Differential phosphorylation, desensitization, and internalization of alpha1A-adrenoceptors activated by norepinephrine and oxymetazoline. Mol Pharmacol. 2013 Apr;83(4):870-81. doi: 10.1124/mol.112.082313. Epub 2013 Jan  30.</citation>
          </article>
          <article>
            <ref-id>A18261</ref-id>
            <pubmed-id>21948594</pubmed-id>
            <citation>Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777.  Epub 2011 Sep 23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35368" source="Swiss-Prot">
        <name>Alpha-1B adrenergic receptor</name>
        <general-function>Protein heterodimerization activity</general-function>
        <specific-function>This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.</specific-function>
        <gene-name>ADRA1B</gene-name>
        <locus>5q23-q32</locus>
        <cellular-location>Nucleus membrane</cellular-location>
        <transmembrane-regions>46-70
84-105
116-141
162-184
202-224
296-319
327-351</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.79</theoretical-pi>
        <molecular-weight>56835.375</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:278</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA1B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M99589</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>23</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>23</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35368</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA1B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Alpha-1B adrenoceptor</synonym>
          <synonym>Alpha-1B adrenoreceptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010399|Alpha-1B adrenergic receptor
MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGLVLGAFILFAI
VGNILVILSVACNRHLRTPTNYFIVNLAMADLLLSFTVLPFSAALEVLGYWVLGRIFCDI
WAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGP
LLGWKEPAPNDDKECGVTEEPFYALFSSLGSFYIPLAVILVMYCRVYIVAKRTTKNLEAG
VMKEMSNSKELTLRIHSKNFHEDTLSSTKAKGHNPRSSIAVKLFKFSREKKAAKTLGIVV
GMFILCWLPFFIALPLGSLFSTLKPPDAVFKVVFWLGYFNSCLNPIIYPCSSKEFKRAFV
RILGCQCRGRGRRRRRRRRRLGGCAYTYRPWTRGGSLERSQSRKDSLDDSGSCLSGSQRT
LPSASPSPGYLGRGAPPPVELCAFPEWKAPGALLSLPAPEPPGRRGRHDSGPLFTFKLLT
EPESPGTDGGASNGGCEAAADVANGQPGFKSNMPLAPGQF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010400|Alpha-1B adrenergic receptor (ADRA1B)
ATGAATCCCGACCTGGACACCGGCCACAACACATCAGCACCTGCCCACTGGGGAGAGTTG
AAAAATGCCAACTTCACTGGCCCCAACCAGACCTCGAGCAACTCCACACTGCCCCAGCTG
GACATCACCAGGGCCATCTCTGTGGGCCTGGTGCTGGGCGCCTTCATCCTCTTTGCCATC
GTGGGCAACATCCTAGTCATCTTGTCTGTGGCCTGCAACCGGCACCTGCGGACGCCCACC
AACTACTTCATTGTCAACCTGGCCATGGCCGACCTGCTGTTGAGCTTCACCGTCCTGCCC
TTCTCAGCGGCCCTAGAGGTGCTCGGCTACTGGGTGCTGGGGCGGATCTTCTGTGACATC
TGGGCAGCCGTGGATGTCCTGTGCTGCACAGCGTCCATTCTGAGCCTGTGCGCCATCTCC
ATCGATCGCTACATCGGGGTGCGCTACTCTCTGCAGTATCCCACGCTGGTCACCCGGAGG
AAGGCCATCTTGGCGCTGCTCAGTGTCTGGGTCTTGTCCACCGTCATCTCCATCGGGCCT
CTCCTTGGGTGGAAGGAGCCGGCACCCAACGATGACAAGGAGTGCGGGGTCACCGAAGAA
CCCTTCTATGCCCTCTTCTCCTCTCTGGGCTCCTTCTACATCCCTCTGGCGGTCATTCTA
GTCATGTACTGCCGTGTCTATATAGTGGCCAAGAGAACCACCAAGAACCTAGAGGCAGGA
GTCATGAAGGAGATGTCCAACTCCAAGGAGCTGACCCTGAGGATCCATTCCAAGAACTTT
CACGAGGACACCCTTAGCAGTACCAAGGCCAAGGGCCACAACCCCAGGAGTTCCATAGCT
GTCAAACTTTTTAAGTTCTCCAGGGAAAAGAAAGCAGCTAAGACGTTGGGCATTGTGGTC
GGTATGTTCATCTTGTGCTGGCTACCCTTCTTCATCGCTCTACCGCTTGGCTCCTTGTTC
TCCACCCTGAAGCCCCCCGACGCCGTGTTCAAGGTGGTGTTCTGGCTGGGCTACTTCAAC
AGCTGCCTCAACCCCATCATCTACCCATGCTCCAGCAAGGAGTTCAAGCGCGCTTTCGTG
CGCATCCTCGGGTGCCAGTGCCGCGGCCGCGGCCGCCGCCGACGCCGCCGCCGCCGTCGC
CTGGGCGGCTGCGCCTACACCTACCGGCCGTGGACGCGCGGCGGCTCGCTGGAGCGCTCG
CAGTCGCGCAAGGACTCGCTGGACGACAGCGGCAGCTGCCTGAGCGGCAGCCAGCGGACC
CTGCCCTCGGCCTCGCCGAGCCCGGGCTACCTGGGCCGCGGCGCGCCACCGCCAGTCGAG
CTGTGCGCCTTCCCCGAGTGGAAGGCGCCCGGCGCCCTCCTGAGCCTGCCCGCGCCTGAG
CCCCCCGGCCGCCGCGGCCGCCACGACTCGGGCCCGCTCTTCACCTTCAAGCTCCTGACC
GAGCCCGAGAGCCCCGGGACCGACGGCGGCGCCAGCAACGGAGGCTGCGAGGCCGCGGCC
GACGTGGCCAACGGGCAGCCGGGCTTCAAAAGCAACATGCCCCTGGCGCCCGGGCAGTTT
TAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha1-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood vessel remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organismal development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glycogen catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organ growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glycogen catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of heart rate by epinephrine-norepinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of the force of heart contraction by epinephrine-norepinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction of artery involved in baroreceptor response to lowering of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0000715</id>
      <name>Alpha-1D adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6969</ref-id>
            <pubmed-id>20030735</pubmed-id>
            <citation>Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x.</citation>
          </article>
          <article>
            <ref-id>A18283</ref-id>
            <pubmed-id>23364786</pubmed-id>
            <citation>Akinaga J, Lima V, Kiguti LR, Hebeler-Barbosa F, Alcantara-Hernandez R, Garcia-Sainz JA, Pupo AS: Differential phosphorylation, desensitization, and internalization of alpha1A-adrenoceptors activated by norepinephrine and oxymetazoline. Mol Pharmacol. 2013 Apr;83(4):870-81. doi: 10.1124/mol.112.082313. Epub 2013 Jan  30.</citation>
          </article>
          <article>
            <ref-id>A18261</ref-id>
            <pubmed-id>21948594</pubmed-id>
            <citation>Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777.  Epub 2011 Sep 23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P25100" source="Swiss-Prot">
        <name>Alpha-1D adrenergic receptor</name>
        <general-function>Alpha1-adrenergic receptor activity</general-function>
        <specific-function>This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.</specific-function>
        <gene-name>ADRA1D</gene-name>
        <locus>20p13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>96-121
134-159
170-192
214-238
252-275
349-373
381-405</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.44</theoretical-pi>
        <molecular-weight>60462.205</molecular-weight>
        <chromosome-location>20</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:280</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA1D</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M76446</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177807</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>24</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>24</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P25100</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA1D_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRA1A</synonym>
          <synonym>Alpha-1A adrenergic receptor</synonym>
          <synonym>Alpha-1D adrenoceptor</synonym>
          <synonym>Alpha-1D adrenoreceptor</synonym>
          <synonym>Alpha-adrenergic receptor 1a</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019001|Alpha-1D adrenergic receptor
MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGAGGGGGVVGAG
SGEDNRSSAGEPGSAGAGGDVNGTAAVGGLVVSAQGVGVGVFLAAFILMAVAGNLLVILS
VACNRHLQTVTNYFIVNLAVADLLLSATVLPFSATMEVLGFWAFGRAFCDVWAAVDVLCC
TASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWVVALVVSVGPLLGWKEPVP
PDERFCGITEEAGYAVFSSVCSFYLPMAVIVVMYCRVYVVARSTTRSLEAGVKRERGKAS
EVVLRIHCRGAATGADGAHGMRSAKGHTFRSSLSVRLLKFSREKKAAKTLAIVVGVFVLC
WFPFFFVLPLGSLFPQLKPSEGVFKVIFWLGYFNSCVNPLIYPCSSREFKRAFLRLLRCQ
CRRRRRRRPLWRVYGHHWRASTSGLRQDCAPSSGDAPPGAPLALTALPDPDPEPPGTPEM
QAPVASRRKPPSAFREWRLLGPFRRPTTQLRAKVSSLSHKIRAGGAQRAEAACAQRSEVE
AVSLGVPHEVAEGATCQAYELADYSNLRETDI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019002|Alpha-1D adrenergic receptor (ADRA1D)
ATGACTTTCCGCGATCTCCTGAGCGTCAGTTTCGAGGGACCCCGCCCGGACAGCAGCGCA
GGGGGCTCCAGCGCGGGCGGCGGCGGGGGCAGCGCGGGCGGCGCGGCCCCCTCGGAGGGC
CCGGCGGTGGGCGGCGTGCCGGGGGGCGCGGGCGGCGGCGGCGGCGTGGTGGGCGCAGGC
AGCGGCGAGGACAACCGGAGCTCCGCGGGGGAGCCGGGGAGCGCGGGCGCGGGCGGCGAC
GTGAATGGCACGGCGGCCGTCGGGGGACTGGTGGTGAGCGCGCAGGGCGTGGGCGTGGGC
GTCTTCCTGGCAGCCTTCATCCTTATGGCCGTGGCAGGTAACCTGCTTGTCATCCTCTCA
GTGGCCTGCAACCGCCACCTGCAGACCGTCACCAACTATTTCATCGTGAACCTGGCCGTG
GCCGACCTGCTGCTGAGCGCCACCGTACTGCCCTTCTCGGCCACCATGGAGGTTCTGGGC
TTCTGGGCCTTTGGCCGCGCCTTCTGCGACGTATGGGCCGCCGTGGACGTGCTGTGCTGC
ACGGCCTCCATCCTCAGCCTCTGCACCATCTCCGTGGACCGGTACGTGGGCGTGCGCCAC
TCACTCAAGTACCCAGCCATCATGACCGAGCGCAAGGCGGCCGCCATCCTGGCCCTGCTC
TGGGTCGTAGCCCTGGTGGTGTCCGTAGGGCCCCTGCTGGGCTGGAAGGAGCCCGTGCCC
CCTGACGAGCGCTTCTGCGGTATCACCGAGGAGGCGGGCTACGCTGTCTTCTCCTCCGTG
TGCTCCTTCTACCTGCCCATGGCGGTCATCGTGGTCATGTACTGCCGCGTGTACGTGGTC
GCGCGCAGCACCACGCGCAGCCTCGAGGCGGGCGTCAAGCGCGAGCGAGGCAAGGCCTCC
GAGGTGGTGCTGCGCATCCACTGTCGCGGCGCGGCCACGGGCGCCGACGGGGCGCACGGC
ATGCGCAGCGCCAAGGGCCACACCTTCCGCAGCTCGCTCTCCGTGCGCCTGCTCAAGTTC
TCCCGTGAGAAGAAAGCGGCCAAGACTCTGGCCATCGTCGTGGGTGTCTTCGTGCTCTGC
TGGTTCCCTTTCTTCTTTGTCCTGCCGCTCGGCTCCTTGTTCCCGCAGCTGAAGCCATCG
GAGGGCGTCTTCAAGGTCATCTTCTGGCTCGGCTACTTCAACAGCTGCGTGAACCCGCTC
ATCTACCCCTGTTCCAGCCGCGAGTTCAAGCGCGCCTTCCTCCGTCTCCTGCGCTGCCAG
TGCCGTCGTCGCCGGCGCCGCCGCCCTCTCTGGCGTGTCTACGGCCACCACTGGCGGGCC
TCCACCAGCGGCCTGCGCCAGGACTGCGCCCCGAGTTCGGGCGACGCGCCCCCCGGAGCG
CCGCTGGCCCTCACCGCGCTCCCCGACCCCGACCCCGAACCCCCAGGCACGCCCGAGATG
CAGGCTCCGGTCGCCAGCCGTCGAAAGCCACCCAGCGCCTTCCGCGAGTGGAGGCTGCTG
GGGCCGTTCCGGAGACCCACGACCCAGCTGCGCGCCAAAGTCTCCAGCCTGTCGCACAAG
ATCCGCGCCGGGGGCGCGCAGCGCGCAGAGGCAGCGTGCGCCCAGCGCTCAGAGGTGGAG
GCTGTGTCCCTAGGCGTCCCACACGAGGTGGCCGAGGGCGCCACCTGCCAGGCCTACGAA
TTGGCCGACTACAGCAACCTACGGGAGACCGATATTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha1-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organismal development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of the force of heart contraction involved in baroreceptor response to increased systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>